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ABSTRACT

Targeting Fat‐Sensitive Pathways In Enteroendocrine Cells Using Nanoparticle‐Mediated
Drug Delivery

by

Bhavik P. Shah, Doctor of Philosophy
Utah State University, 2009

Major Professor: Dr. Timothy A. Gilbertson
Department: Biology

The current epidemic of obesity has been linked to an increase in fat intake
associated with the Western diet. Nutrient‐induced stimulation of enteroendocrine cells
in the small intestine leads to the release of hormones that contribute to satiety and the
control of food intake. In particular, ingested fat, specifically in the form of free fatty
acids, is potent activator of enteroendocrine cells in the proximal small intestine.
However, the underlying signaling cascade that free fatty acids initiate in these
enteroendocrine cells, which leads to secretion of satiety hormones, is not known. In
general, my research is focused on identifying nutrient‐responsive pathways in
enteroendocrine cells involved with the release of satiety signals and using this
information to begin to develop novel drug delivery strategies to reduce food intake. In
general, my results revealed that activation of the fatty acid receptor GPR120 was
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ecessary for the linoleic acid‐induced intracellular calcium rise, a necessary precursor for
hormone release. Using patch clamp recording, I discovered that linoleic acid activated
enteroendocrine cells by inducing membrane depolarization, a process requiring the
calcium‐activated, monovalent cation permeable channel TRPM5, which is activated
downstream of GPR120. To validate the unexpected finding that TRPM5 was involved in
fattyacid signaling, I performed experiments using bitter compounds, whose
transduction pathway is known to involve TRPM5. Enteroendocrine cells express the
bitter taste receptors and release cholecystokinin in response to bitter stimuli,
suggesting the probable role of gut in initiation of protective behavior against ingestion
of potentially harmful substances. Armed with the data on the specifics of the fatty acid
transduction, I performed experiments using nanoparticles to determine their utility for
delivering pharmaceuticals specifically to the enteroendocrine cells. I fabricated and
characterized PLGA nanoparticles and performed intracellular uptake studies in order to
optimally delivery payloads inside cells. Finally, I validated their use by using cell‐based
assays to determine the effects of internalized PLGA nanoparticles on ion channels and
signaling pathways involved in CCK release. Taken together, this dissertation research
has identified the signaling pathways (pharmacological targets) involved in fatty acid‐
mediated satiety hormone release and validated the potential therapeutic use of
nanoparticle‐mediated drug delivery for the eventual control of food intake.
(168 pages)
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CHAPTER 1
INTRODUCTION

Rationale for Proposed Research
Obesity is one of the most common health problems within the world’s
population. In its simplest terms, obesity is an imbalance of energy intake and
expenditure over the long term resulting in excessive fat accumulation in the body.
More than 250 million people (~ 7% of adult population) in the world are considered
obese.

By current estimates, 30% of U.S. adults are obese—roughly double the

percentage 20 years ago—and another 35% are overweight. Obesity can lead to other
life threatening diseases like Type II diabetes, heart attack, stroke, end stage renal
disease and some types of cancer including breast and colon cancers. Indeed, some
300,000 people die from obesity related diseases every year in the United States alone.
Obesity is not simply a cosmetic problem affecting a subset of individuals, but an
epidemic that threatens global well being. To begin to think about ways to ameliorate
the epidemic of obesity, it is first important to understand the underlying mechanisms
in the body dealing with the balance between food intake and energy expenditure.
The type and amount of food that we eat varies considerably from meal to meal
and from day to day. Food intake is influenced by emotional and social factors, the time
of day, convenience and cost, which are not biologically regulated. As a consequence,
daily energy intake is variable both within and between individuals and is not well
correlated with daily energy expenditure (31). Despite short‐term mismatches in energy
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balance, however, most individuals match cumulative energy intake to energy
expenditure with great precision when measured over a period that spans many meals
(31). This phenomenon is called energy homeostasis which actively regulates the
optimal level of nutrients in organs (i.e. fat in adipose tissue) and in blood (sugar). In
order to achieve energy homeostasis the central nervous system (CNS) continuously
receives and accurately processes energy‐related information from receptors which
monitor food intake as well as energy store levels. These energy‐related signals
(metabolic, neural and endocrine signals) are integrated by the brain and, in turn, the
brain sends commands to those areas controlling energy intake and expenditure in an
attempt to balance energy intake utilization over long periods of time. Thus, the brain
can respond to novel or ongoing demands via well coordinated responses as well as to
anticipate changes in energy availability and make responses to avoid large shortfalls.
Despite the aforementioned coordination of energy expenditure and energy
intake, most mammals take their meals in discrete episodes and the initiation of these
meals is rarely based on acute biological deficits like insufficient glucose. Rather it
depends on routine habits, time of day, social situations and other factors (120). If one
assumes that energy intake and energy expenditure regulate body weight then there
should be some regulatory mechanism to limit the amount of food ingested or calories
consumed during individual bouts of feeding. Consistent with this idea, gastrointestinal
hormonal secretions during meals are proportional to the amount of calories consumed,
and some of these hormones induce the sensations of satiation (i.e., fullness, or signals
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that contribute to the decision to terminate an ongoing meal) and satiety (i.e., signals
that function to prolong the interval until hunger or a drive to eat reappears). These
acutely acting signals are collectively called ‘‘satiety signals,’’ and the prototypical
example of a satiety hormone is cholecystokinin (CCK) (85, 119, 134). In contrast with
these acutely acting satiety signals, adiposity signals act continuously to inform the brain
regarding total body fat levels (3, 100, 135). The prototypical examples of adiposity
hormones are insulin and leptin. These hormones are secreted from pancreatic beta
cells and adipose tissue (also from gastrointestinal tract, stomach), respectively, and
their secretion is proportional to total body fat. Thus, long‐term regulation and
maintenance of stable body weight is achieved through effective integration of short‐
term, meal‐related satiety signals and adiposity signals indicating body fat stores (114,
136).

Satiety Signals
As discussed, the body must have a means of measuring reliably how many
calories have been ingested within a meal in order to maintain energy homeostasis.
Initially, scientists thought number of parameters like the sight, smell or taste of food
could provide negative feedback signals during a meal to terminate further
consumption. However, a number of sham feeding experiments have provided evidence
that smell, sight or taste alone does not provide the cues necessary to stop food intake.
In sham feeding experiments, animals are implanted with a gastric fistula in the
stomach. When the fistula is closed food ingested can pass normally through stomach

4
and then enter the duodenum. However, when the fistula is open (sham feeding) food
passes out the digestive system through the fistula, bypassing the small intestine. As
expected, when the fistula is closed animals ate normally (size and duration of the
meal), but in the sham feeding condition (fistula open), animals ate larger and longer
meals even though the taste, sight and smell conditions were equivalent in both
conditions. From these experiments one could assume that there is some factor or
factors (satiety signals) released as nutrients enter the small intestine that contributes
to the termination of food intake (27).
As is now known, the chemical constituents of ingested food interact with
receptors on specialized endocrine cells in the stomach and intestine that activate
secretion of a complex array of peptides. These signals function to optimize the
digestive process as well as to induce satiety. These gastrointestinal peptides are
released from specific enteroendocrine cells having finger‐like projections (microvilli)
that contain the chemoreceptors sensitive to nutrients and other constituents of the
chyme (70, 78, 103, 104, 109). These specialized enteroendocrine cells actually
represent a very small percentage of the total enterocyte population. Of the several
different types of gastrointestinal hormones that have been identified, most function as
satiety signals (119). The exception is the recently identified hormone ghrelin, which
stimulates hunger and food intake. Table 1.1 summarizes these hormones and the cells
which secrete them. Apparently, different populations of enteroendocrine cells are
sensitive to different nutrients (e.g., carbohydrates, fats, proteins) (63, 98, 103, 107,
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127, 139).
Following their secretion, these gastrointestinal satiety peptides either enter the
bloodstream and act on the liver, gallbladder, pancreas and brain in an endocrine
fashion or they diffuse into the interstitial fluid to influence neighboring cells in a
paracrine manner (52, 103, 105). These satiety signals are thought to influence food
intake by activating the neurons in the nucleus tractus solitarius (NTS), an area of the
caudal brain stem that integrates sensory inputs from abdominal viscera, GI tract, as
well as taste information from the oral cavity (106). They activate these neurons in hind
brain either by activating vagal afferent nerve fibers (e.g. CCK acts on CCK‐1 receptors,
paracrine mechanism) which extends from the GI tract to the hind brain; alternatively,
these satiety hormones circulate to the hindbrain via blood and activate neurons
directly (e.g. amylin, endocrine mechanism). Among the gastrointestinal hormones, CCK
has been the best characterized. As shown in the Table 1.1, duodenal enteroendocrine
Type‐I cells secrete CCK in response to different nutrients.
Three decades ago Gibbs and colleagues (35) discovered that administration of
synthetic or purified CCK can reduce meal size in dose‐dependent manner without
inducing any kind of gastrointestinal malaise in the animals. CCK elicits satiety through
activation of CCK‐1 receptors present in vagal afferents. This was confirmed by
administering a CCK‐1 receptor antagonist that caused increased food intake in animals
(4, 49). In the GI tract, endogenous CCK plays several roles such as gallbladder
contraction, pancreatic enzyme secretion, inhibition of gastric emptying, and
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stimulation of intestinal motility (39, 112). CCK acts acutely as a short‐term meal
termination signal. Experiments using repeated or long‐term continuous administration
of exogenous CCK induced no change in total food intake and were not effective at
inducing long‐term weight loss (25, 131). Interestingly, administration of CCK before
each meal reduced meal size in animals, however, animals increased meal frequency
when provided with food ad libitum (131, 132) and overall energy intake was similar
suggesting that exogenous CCK administration may not be a useful strategy to induce
weight loss in animals. The caveat in these data is that the exogenous CCK‐8 used in this
experiment has a very short half‐life and time constant of action indicating, longer
acting CCK analogs may hold promise as potential weight loss drugs. Given that humans
tend to eat the majority of their calories in three discrete meals each day,
administration of CCK or its analogs before a meal may be a more viable weight loss
strategy for humans than for animals.
Like CCK, the other gastrointestinal peptides mentioned in Table 1.1 with the
exception of ghrelin are involved in reducing meal size when administered systemically.
These hormones are elevated during/after a meal, while ghrelin levels are elevated
before a meal (26, 126) and are very low during and after meals (125). Exogenous
ghrelin administration stimulates hunger and causes animals and humans to consume
larger meals (124, 137).

Hence, CCK and ghrelin work in fundamentally opposite

manners. Thus, like enhancement of CCK release, inhibition of ghrelin action could lead
to a reduction in food intake.
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In summary, when food is eaten, nutrients interact with receptors lining the
stomach and intestine causing the release of peptides and other factors that coordinate
the process of digestion with the particular food being consumed. Some of the peptides
provide a signal to the nervous system, and as the integrated signal accumulates, it
ultimately creates the sensation of fullness and contributes to cessation of eating.
Administering the same peptides exogenously elicits a dose‐dependent reduction of
meal size, whereas administering antagonists (e.g., for CCK) or antisera (e.g., for
apolipoprotein A‐IV) causes increased meal size.

Adiposity Signals
As mentioned, insulin and leptin are secreted into the blood in proportion to the
total fat stored in the body. These hormones circulate through blood and cross the
blood brain barrier and bind to their respective receptors and start very complex
signaling cascades dealing with maintenance of energy homeostasis. As leptin and
insulin are secreted in proportion to the total body fat, neurons sensitive to leptin and
insulin receive signals proportional to total body fat. Along the same line, when either of
the adiposity hormones was administered locally inside the brain, animals exhibited a
reduction in food intake and showed weight loss. Conversely, when insulin and leptin
levels were reduced in the brain, individuals increased their food intake and gained
weight responding in a manner that suggested there were insufficient fat stores in the
body. The correlation among adiposity hormone levels, fat stores and food intake has
been the subject of a number of excellent reviews (114, 136).
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These effects of leptin and insulin related to energy homeostasis are at least
partially mediated through the arcuate nucleus in the forebrain (21). The arcuate
nucleus consists of 2 different types of neurons where receptors for leptin and insulin
are co‐expressed. The first type of arcuate neuron, called proopiomelanocortin (POMC)
neurons, synthesize the peptides POMC and cocaine and amphetamine regulated
transcript (CART) (33). These POMC neurons secret melanocyte stimulating hormone
(alpha‐MSH) (20) which, in turn, activates neurons in the paraventricular nucleus (PVN)
of the hypothalamus and eventually reduces food intake by binding to the melanocortin
3 (MC3R) and melanocortin 4 (MC4R) receptors (77, 128). Thus, leptin and insulin
initiate this catabolic pathway through initiating the alpha‐MSH signaling cascade
mediated by MC3R/MC4R. The second type of arcuate neuron synthesizes and releases
two peptides called agouti related peptide (AgRP) and neuropeptide Y (NPY). These two
peptides are involved in initiation of anabolic pathways in the body. AgRP is an reverse
agonist of MC3R and MC4R (45, 46, 108) and thus blocks the anorectic effect of leptin
and insulin. Neuropeptide Y stimulates food intake by acting on different receptors (Y1
& Y5) (17, 65).
The expression of NPY and AgRP mRNA is severely down regulated in the arcuate
nucleus by the presence of leptin and insulin near the arcuate nucleus (80, 113). Thus,
the arcuate nucleus is considered a key center which matches food intake with the
nutritional status of the body and specifically the activity of POMC and AgRP/NPY
neurons determines whether an individual will gain or lose weight. Transgenic animal
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models have also indicated that it is important for the brain to know about the current
nutritional status of the body to control food intake and eventually energy balance.
Mouse models (db/db) carrying leptin resistance become hyperphagic and extremely
obese because the brain is not aware of the current nutritional status of the body. The
neuronal circuitry underlying energy homeostasis is shown in Fig. 1.1.

How Are Adiposity and Satiety Signals Integrated?
There is compelling evidence suggesting that the efficacy of satiety signals to
terminate a meal varies with the relative amount of fat in the body; and this, in turn, is
signaled to the brain by the adiposity hormones, leptin and insulin. When an individual
has been on a diet and loses weight, leptin and insulin levels in the plasma decline,
reducing the adiposity signals reaching the hypothalamus. This then lowers sensitivity to
satiety signals such as CCK or bombesin‐family peptides, and hence more calories are
taken in before satiety occurs. As described above, adiposity signals act on the forebrain
(arcuate nucleus) to initiate their effects (catabolic/anabolic) and satiety signals act on
the hindbrain (NTS). This begs the question then: How is the forebrain response to
adiposity signals coupled to changes in the size of single meals? Anatomically, there are
reciprocal interconnections between NTS neurons and forebrain centers like the PVN
(123). There is also evidence that receptors (e.g. MC4) for the central effector peptides
involved in energy homeostasis are also expressed in NTS neurons (86) and when MC4
agonists are administered locally to NTS, feeding responses were elicited as expected
(40). These findings, combined with fact that presence of leptin receptors (79) and
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POMC neurons (11) in NTS region, indicate the fact that forebrain and hindbrain both
process energy homeostasis related information. Thus, the NTS or other brainstem
areas may, like the arcuate nucleus, contain neurons that respond to leptin and, through
ascending projections to key forebrain sites, contribute to adaptive feeding responses to
changes in body fat content.
Given that leptin and insulin are anorectic compounds, one would think to use
them or their agonists as weight loss drugs. The fact that these peptides have their main
energy homeostatic action in the brain limits their utility since the administration of
these compounds typically must be done systemically. Administering insulin systemically
would lead to hypoglycemia and hypoglycemia, in turn, leads to increase in food intake
(41, 69), thus working against the therapeutic intent. To date, leptin has not been shown
to lead to any significant body weight loss in animals or in human with obesity, probably
due to their leptin resistant state (43).

Factors Influencing Obesity
Obesity is not single disease but a complex group of disorders with multiple
causes. Factors influencing obesity are mainly categorized in to two main categories,
genetic factors and environmental factors (Fig. 1.2). It has been estimated that genetic
factors, such as mutations in the leptin receptor, comprise less than 5% of cases of
obesity. Obesity is largely influenced by interactions of environmental and psychosocial
factors. These environmental factors are acting through the physiological mediators of
energy intake and expenditure. It is generally accepted that the increase in food intake
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(typified by increased consumption of calorically dense diets) coupled with a decrease in
energy expenditure (increased sedentary behaviors) are the main reasons for the
obesity epidemic in the last two decades. In particular, the increase in fat consumption
typical in the Western diet may be a strong contributor to the increase in energy intake
linked with obesity. It is well know that high fat diets are highly palatable and they may
lead to the over‐consumption of tasty food. Animals or humans kept on a high fat diet
increase their body fat mass and body weight. Lowering the proportion of energy intake
from dietary fat is a viable strategy that is successfully used in people to keep weight off
(59). Epidemiological studies done by Popkin and Bray demonstrated that increasing
dietary fat is associated with increased prevalence of obesity (Fig. 1.3) (7). As illustrated
in Fig. 1.3, there is direct relationship between dietary fat consumption and occurrence
of obesity in different countries. Popkin and Bray also showed that a reduction in dietary
fat intake can reduce the gap between total food intake and energy expenditure and
thus reduction in dietary fat intake might be a very reasonable strategy to reduce the
incidence of obesity worldwide.
Fat is the most energy dense macronutrient with a caloric density of 9 kcal/gm
compared to the 4 kcal/gm found in protein or carbohydrate. After ingestion, dietary fat
enters the small intestine and is hydrolyzed into free fatty acids and mono‐ and di‐acyl
glycerols by pancreatic lipases. Free fatty acids stimulate the secretion of satiety
hormones CCK and GLP‐1 by activating Type I enteroendocrine cells, which leads to
onset of early satiety. Understanding the mechanisms that the body uses to recognize
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fats, their role in fat intake and their developmental and hormonal plasticity would
seem crucial to develop potential physiological and pharmacological treatments for diet‐
induced obesity. As such, there has been tremendous interest in the identification and
characterization of putative fat receptors. Recent discoveries have identified free fatty
acids as ligands for several GPCRs (10, 12, 55, 64, 140) and identification of fatty acid
activated GPCRs has revolutionized our understanding of fatty acid mediated
physiological functions.

Fatty Acid Activated G‐Protein Coupled Receptors (GPCRS)
GPR41 & 43. GPR41 and GPR43 family share 38% sequence homology with each
other. Although both the proteins are activated by short chain fatty acids (SCFA), they
have different specificity for SCFAs and have different tissue localization and
physiological function (12, 64, 140). Both receptors are activated by the same ligands
with a different rank of potency. The optimal carbon length is 2 to 3 for GPR43 and 3 to
5

for

GPR41.

The

pathways

activated

by

both

these

receptors

include

inositol‐1,4,5‐triphosphate, release of intracellular calcium and ERK1/2 activation and
inhibition of cAMP accumulation (64). However, GPR43 is coupled exclusively to the
pertussis toxin‐sensitive Gi/o family whereas GPR41 is coupled to both Gi/o family and
pertussis toxin‐insensitive Gq families (64). It has been reported that SCFAs stimulate
leptin production in adipocytes and increase circulating leptin levels in the animals
through GPR41 (19). GPR43 was identified as leukocyte‐specific STAT‐induced GPCR
(115). Highest levels of expression of GPR43 were reported in lymphatic tissue,

13
especially peripheral blood leukocytes, suggesting a potential role for GPR43 in immune
cell function and hematopoiesis (115).
GPR84. GPR84 was originally identified in granulocytes (142). Prior to the
identification of its cognate ligands, gene knockout of GPR84 revealed that proliferation
of T and B cells were normal and its function lies in regulating early IL‐4 gene expression
in activated T cells (129). Subsequently, GPR84 has been demonstrated to be activated
by medium‐chain FFAs (C9‐C14) and elicits calcium mobilization (130). GPR84, which is
expressed in immune cells, amplifies pro‐inflammatory cytokine production suggesting
that GPR84 may function in fatty acid mediated immune regulation (6).
GPR40. GPR40 is a receptor for medium chain (C6‐C12) and long chain (C14‐C24)
free fatty acids (10, 55). Both saturated and unsaturated (C18‐C20) free fatty acids are
ligands for GPR40 where the terminal carboxyl group appears important for receptor
activation. GPR40 is preferentially expressed in pancreatic β cells and involved in
FFA‐mediated glucose‐stimulated insulin release (55). It has also been shown that small
molecule agonists of GPR40 receptors promote glucose‐dependent insulin secretion and
reduce blood glucose in mice (9).
GPR120. GPR120 is abundantly expressed in mouse and human intestinal tract
and intestinal endocrine cell line STC‐1, but not in pancreatic cells (50). GPR120 is
coupled to pertussis toxin‐insensitive Gq family of G‐proteins (57). Stimulation of
GPR120 with long chain unsaturated fatty acids leads to secretion of peptides like GLP‐1
and CCK from Type‐I enteroendocrine cells, suggesting its role in induction of early
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satiety and insulin release (50). GPR120 has been shown to mediate FFA inhibition of
serum deprivation‐induced apoptosis in STC‐1 cells (57). Interestingly, expression of
GPR120 has been reported in adipose tissue of mice and humans with levels
up‐regulated in mice on high fat diets and during adipocyte differentiation in 3T3 L1cells
(38). Down‐regulation of GPR120 by siRNA leads to inhibition of adipocyte
differentiation implying a novel role for GPR120 in adipogenesis and potentially obesity
(38). Recently GPR120 has been detected in rat (75) and mouse taste receptor cells
(unpublished data, Gilbertson Laboratory). Further, double immunostaining work
revealed that GPR120 is expressed in Type II taste receptor cells (PLCβ2 and alpha‐
gustducin) (74). These findings collectively suggest that GPR120 might function as
receptor for dietary fat in oral cavity.

Type I Enteroendocrine Cells/STC‐1 Cells
Based on their ultrastructural characteristics, CCK secreting cells in GI tract have
been officially named (Wiesbaden classification) Type I enteroendocrine cells (118).
These cells are mainly concentrated on the duodenum and proximal jejunum. CCK
containing Type I enteroendocrine cells are flask‐shaped with their apical surface
oriented towards the lumen of intestine (99). Various nutrients (fatty acids,
carbohydrates, proteins), tastants and hormones have been shown to release CCK by
activating the aforementioned Type I enteroendocrine cells. The CCK secreting mouse
enteroendocrine cell line, STC‐1 cells, is often used as model system to study Type I
enteroendocrine cells. STC‐1 cells have been used for studying regulation of GI hormone
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release in response to bombesin/gastrin releasing peptide (14, 87, 117), free fatty acids
(50), leptin (42), pituitary adenylate cyclase activating polypeptide (13), orexin (61) and
amino acids (66). Moreover, five basic taste stimuli such as sweet, bitter, umami, salty
and sour have been shown to stimulate STC‐1 cells (110, 138). Also, STC‐1 cells EECs
express all the signaling components identified in Type II taste receptor cells including
alpha gustducin, PLC‐ß2 and TRPM5 ion channels.

Transient Receptor Potential (TRP) Ion Channels: TRPM5
Transient receptor potential (TRP) channels form a large and functionally
versatile family of ion channels that have distinct activation mechanisms and biophysical
properties. TRP channels are expressed in most tissues and play an important role in the
regulation of various cell functions. The first TRP channel was discovered in the studies
that examined Drosophila phototransduction, where trp gene mutations exhibited
transient voltage (potential) responses to continuous light in photoreceptor cells (23,
48). In 1989, Montell et al. cloned the trp gene (83), and Hardie et al. (1992)
subsequently showed that trp gene encodes a Ca2+‐permeable cation channel (48). Since
then, a number of channels with sequence homology to the Drosophila TRP channel
have been found and cloned from worms, flies, and mammals, and form a huge TRP
superfamily. The mammalian TRP superfamily is divided into six subfamilies based on
sequence homology (16, 22, 28, 81, 82, 84, 88‐90, 96). The TRP superfamily includes
TRPC (canonical, TRPC1–7), TRPM (melastatin, TRPM1–8), TRPV (vanilloid, TRPV1–6),
TRPA (ankyrin, TRPA1), TRPP (polycystin) and TRPML (mucolipin) families. Currently,
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significant scientific effort is being devoted to understanding the physiology of TRP
channels and their relationship to human diseases.
TRP channel subunit consists of six putative transmembrane spanning domains
(S1–S6) with a pore‐forming loop between S5 and S6 and intracellularly located NH2 and
COOH termini (16). All TRP channels are known to be cation‐selective. All functionally
characterized TRP channels with exceptions of TRPM4 and TRPM5 are permeable to
calcium ions. TRPM4 and TRPM5 are permeable to monovalent cations.
TRPM5 forms non‐selective monovalent cation specific ion channels. In 2002,
Perez et al. reported that TRPM5 is preferentially expressed in taste tissues and
hypothesized its role in sweet, bitter and umami taste transduction (97). Mice with
targeted deletion of TRPM5 exhibited diminished sensitivity in perception of sweet,
bitter and umami tastants; suggesting that TRPM5 is essential signaling component in
sweet, bitter and umami taste transduction (143). Interestingly, recent studies show
that TRPM5 is sensitive to temperature, pointing to its role in “thermal taste,” i.e.
enhanced sweet perception with increasing temperature (122). For sweet, bitter, and
umami tastants, stimuli binds to GPCRs on the apical surface of the TRCs, activates
PLCβ2, leading to hydrolysis of PIP2 to DAG and IP3, release of intracellular calcium, and
activation of the cation channel TRPM5 (143). In taste receptor cells, activation of
TRPM5 is thought to be involved in inducing depolarization. Behavioral experiments
showed that mice with a targeted deletion of the PLCβ2 gene exhibit diminished
sensitivity to sweet, bitter, and umami stimuli (30, 143). So, it is hypothesized that taste
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transduction involves the PLC signaling cascade which leads to the activation of TRPM5
channels, a signaling pathway very similar to phototransduction in fly eyes. So far, the
idea of how TRPM5 is regulated by PLC signaling is still contradictory. Some studies
show that TRPM5 channels can be directly activated by intracellular Ca2+ (51, 67, 102), or
the depletion of Ca2+ from intracellular stores (97). However, other studies showed that
TRPM5 is not activated by Ca2+, IP3, or depletion of intracellular Ca2+ stores (143). Since
some of the studies were done in cell lines, it remains possible that the heterologously
expressed channels do not fully recapitulate the properties of native channels, which
make the mechanisms even more uncertain. Outside the tongue, TRPM5 is known to be
highly expressed in the GI tract, specifically in enteroendocrine cells. STC‐1 cells also
express TRPM5 along with other taste signaling components (15). The role of TRPM5 in
these cells has yet to be determined.

Fatty Acid Signaling in STC‐1 Cells
Recently, Hirasawa et al. (50) demonstrated that the long chain PUFA receptor
GPR120 is abundantly expressed in the proximal small intestine and in a Type I
enteroendocrine cell line, STC‐1, and plays a crucial role in fatty acid‐induced GLP‐1
secretion from Type I enteroendocrine cells.. There are groups of fatty acid specific
GPCRs expressed in Type I enteroendocrine cells in the proximal small intestine. These
receptors include the aforementioned GPR40, GPR41, GPR43 [unpublished data from
the Gilbertson Laboratory]. Long chain PUFA binds GPR120 and elicits a rise in
intracellular calcium concentration which is necessary and sufficient for secretion of
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satiety hormones like CCK and GLP‐1. A working model for long chain PUFA induced CCK
release is showed in Fig. 1.4.
As illustrated in Fig. 1.4, delayed rectifying potassium (DRK) may play a role
either as a direct “receptor” for fatty acids or may enhance the depolarization
generated by GPCR activation upstream. The role of DRK channels as putative fat
receptors has been shown in the peripheral gustatory system, where inhibition of DRK
channels in mammalian taste receptor cells (TRCs) has been proposed as a mechanism
underlying the taste of fat. The studies from our laboratory in obesity‐prone and
‐resistant rats suggest that the ratio of fatty acid‐sensitive (fa‐s) to fatty acid‐insensitive
(fa‐i) delayed rectifying K+ channels contributes to differences in dietary fat preference
(36). Using heterologous expression, I have determined that the KCNA & KCNB DRK
families are fa‐s channels, while the KCNC family is fa‐i. To check that the ratio of fa‐s:fa‐
i DRK channels is correlated with fatty acid responsiveness, I have attempted to
overexpress a fa‐i channel (KCNC1) or a fa‐s channel (KCNA5) in an enteroendocrine cell
line (STC‐1). STC‐1 cells respond to polyunsaturated fatty acids (PUFAs) in a similar
fashion to taste receptor cells (TRCs). Using patch clamp recording, I have examined the
effect of linoleic acid (10 µM) on DRK currents in STC cells cotransfected with GFP and
either KCNA5 or KCNC1. Overexpression of the fa‐i KCNC1 channel leads to a marked
reduction in fatty acid responsiveness. Conversely over expressing KCNA5 channels
enhanced the fatty acid responsiveness, consistent with my model. DRK channel block
by fatty acid causes depolarization of STC‐1 cells and depolarization causes hormone
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release (Fig. 1.4). Therefore I hypothesize that these channels are playing a major role in
fatty acid transduction in STC‐1 cells and by consequence in fatty acid induced hormone
release.
Various anorectic drugs that suppress appetite were widely used for the
treatment of obesity. These drugs are believed to decrease food intake through their
effects on catecholamine or 5‐hydroxytryptamine (5‐HT) levels in the brain (37). Besides
modest therapeutic efficacy, they cause severe side effects like pulmonary
hypertension, development of valvular heart disease, hypertension, and stroke. Most of
the drugs, including Redux (dexfenfluramine/phentermine), cause severe side effects
have subsequently been banned from the market. In addition to their role as serotonin
releasing agents or serotonin uptake inhibitors, the most common feature shared by all
these anorectic drugs is their ability to inhibit voltage‐gated DRK channels (Kv) (53).
Because of their importance in the transduction of fat, the common inhibitory effect on
potassium channels might contribute to their anorectic effect as well as cause
detrimental cardiovascular side effects by their long term use [67]. It is my working
hypothesis that either there should be new therapeutic targets (such as those shown in
Fig. 1.4) or novel drug delivery methods which can deliver clinically effective anorectics
to reduce these detrimental side effects and maintain therapeutic efficiency and in this
way control food intake and help control the burgeoning epidemic of obesity.

Nanoparticles
Conventional methods for drug administration mainly include oral and
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intravenous administration. It is very common that patients often have side effects if the
drugs are administered in a conventional way. Due to lack of localized delivery, the
drugs that are meant to be delivered to diseased tissues or organs may also be delivered
to the liver, kidneys, or other visceral organs, causing several problems such as
inadequate dosage for the diseased tissues and toxicity for the healthy tissues.
Development of targeting and drug delivery carriers such as nanoparticles is an
attractive strategy to overcome these side effects and to increase the effectiveness of
drug delivery. Nanoparticle systems are now used for in vivo delivery of pharmaceutical
compounds in pharmaceutical research and clinical settings. Nanoparticle systems are
defined as a colloidal system with diameters less than 1 µm (8). Drug‐ or gene‐
containing nanoparticles have the ability to deliver the payloads largely, if not
exclusively, to the tissue or cells of interest. Site specific delivery of nanoparticles is
achieved through the inclusion of specific antibodies or lectins (to recognize specific
carbohydrates present on cell surface) conjugated on the nanoparticles which can
recognize the unique receptors expressed on the cells of interest. Figure 1.5 shows the
schematic of nanoparticles containing their payloads.
This nanoparticle‐mediated targeted drug delivery method has several
advantages over traditional drug delivery methods. Notable advantages include: 1)
Negligible side effects due to site specific drug delivery; 2) improved bioavailability of
drugs at therapeutically desirable levels; 3) reduction in amount of drug needed as well
as number of dosages; 4) ability of certain types of nanoparticles to cross the blood
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brain barrier; 5) controlled drug release; 6) intracellular compartment targeting; and 7)
pharmaceuticals (peptides, gene etc.) with relatively short half lives can be used within
the nanoparticle.
Advantages 1‐3 are very important because adverse drug effects are responsible
for approximately 15% of total hospital admissions, more than 100,000 deaths and at
least 136 billion USD in American health care costs each year (18, 24). However, the
advantages mentioned above must be weighed against potential problems. These
potential concerns may include: 1) toxicity of the material or the degradation products
of the material used to make the particles in the body; 2) different nanoparticles can
easily get internalized into the cells and can interfere with normal cell physiology (gene
expression, protein trafficking, ion channel function, cell signaling); 3) immune host
response due to recognition of the nanoparticle material as foreign; 4) discomfort
caused by drug delivery system itself or the physical insertion of the system; and 5)
these systems might be expensive because of the costs to design, formulate, and store
them. Though still in its relative infancy, the use of nanoparticle‐mediated drug delivery
strategies is growing. In recent years a number of different types of nanoparticles have
been fabricated from materials including organometallics, ceramics, different lipids and
phospholipids, and polymers (biodegradable and non‐biodegradable). The next few
sections will briefly discuss the various materials used in current nanoparticle
technology.
Magnetic nanoparticles (MNPs). There has been considerable interest in recent
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years to develop magnetic nanoparticles as a system for delivering therapeutic reagents
to the cell/tissue of interest. However, complications such as cytotoxicity and
aggregation of magnetic nanoparticles have limited their use in the medical field.
Despite these undesirable characteristics, magnetic nanoparticles have unique features
like high level tissue accumulation and non‐invasive imaging. These unique features
make them very attractive candidates for the medical application. Ferrous oxide and
ferric oxide are the most extensively used magnetic nanoparticles in biotechnology
applications; however, other metals, such as cobalt and nickel, are also used in other
applications [111]. Ferrous oxide nanoparticles are broken down in to oxygen and iron
inside body, which fits into the metabolic pathways and thus have very low cytotoxicity.
Currently, MNPs are attractive candidate for the MRI as they can be potentially used as
contrasting agents.
Ceramic nanoparticles. Ceramic nanoparticles are made out of inorganic
biocompatible compounds like silica, titania and alumina. The ease in controlling the
porosity and size of the particles makes them excellent drug delivery vehicles. Further,
these particles provide near total protection of entrapped pharmaceutical agents from
the hostile pH environment found in many regions in the body. It has been
demonstrated that surface modifications on silica particles leads to effective binding
and the ability of these particles to protect plasmid DNA from degradation (71) makes
them good DNA transfection carriers. The drawback of these nanoparticles lies in their
non‐biodegradable nature, necessitating their need to be eliminated from the body.
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Lipsomes. Lipsomes are lipid bilayer spheres in which an aqueous volume is
enclosed by the membranous lipid bilayer. Lipid components in the bilayer consist of
cholesterols and natural as well as synthetic non‐toxic phospholipids. Liposome systems
have a number of advantages in terms of amphiphilic nature, biocompatibility,
controlled drug release, no cytotoxicity of their degradation products (fatty acids), and
the ease of surface modification. Due to the list of advantages mentioned above they
remain one of the most efficient and widely used drug delivery carriers. Liposomes can
alter the pharmacokinetics properties of drugs especially for proteins and peptides (1).
Surface modification of liposomes by polyethylene glycol (PEG) can increase their
circulating half life (62) and these liposomes are called “stealth liposomes.” FDA granted
full approval for doxorubicin HCl liposome (Doxil, marketed by Tibotec Therapeutics) for
the treatment of patients with ovarian cancer whose disease has progressed or recurred
after platinum‐based chemotherapy.
Solid lipid nanoparticles (SLNs). Solid lipid particles were developed in the early
1990s as an alternative drug delivery system to emulsions, liposomes and polymeric
nanoparticles. Solid lipid particle (SLN) is another lipid based formulation which is
already in use as drug delivery system for humans. These particles consist of solid
hydrophobic core covered with lipid monolayer. Drug dissolved in high melting fat
matrix makes the solid hydrophobic core of SLNs and hydrocarbon chains of
phospholipids are embedded within hydrophobic core. SLN have been developed and
used for different administration routes like parental (58, 133), pulmonal (34) and
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dermal (29, 73). Degradation rate of the SLNs can be modified using different
surfactants and can be used as controlled drug release system (92). SLNs are nontoxic
compared to polymeric nanoparticles. Cationic SLNs can be used as an very effective
non‐viral gene transfection vehicles (91). The first commercial SLN formulation has
reached market with the name Nanobase. SLN serves as a good alternative drug delivery
system to existing systems in terms of biodegradability, tolerability and cost
effectiveness, thereby establishing its way to the pharmaceutical industry.
Polymeric Nanoparticles (PNPs). Polymeric nanoparticles are made from
biodegradable and biocompatible polymers have had an enormous impact on controlled
and targeted drug therapies (60). PNPs are fabricated from synthetic, semi‐synthetic
and natural polymers and vary in size from 10 nm to 1000 nm. Depending upon the
method of preparation, nanospheres, or nanocapsules can be obtained in which drug
either is dissolved, entrapped, encapsulated or attached to the nanoparticle matrix.
Polymeric materials exhibit several desirable properties including biocompatibility,
biodegradability, surface modification, and ease of functionalization of polymers.
Polymeric systems allow for a greater control of pharmacokinetic behavior of the loaded
drug, leading to therapeutically desirable drug levels for longer time.
Biodegradable polymeric nanoparticles, typically consist of different polymers
like polylactic acid (PLA), polyglycolic acid (PGA), poly(ε‐caprolactone) (PCL), polylactic‐
glycolic acid (PLGA), and polymethyl methacrylate (PMMA) that are being investigated
for the delivery of proteins, genes and DNA (5, 94). PLGA (Poly‐(D,L‐lactic‐co‐glycolic
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acid)) based nanoparticles have also proven their ability in enhanced delivery of
antigens to dendritic cells (32). Nanoparticles have also been utilized in the delivery of
antisense oligonucleotides, which are susceptible to degradation by nucleases (2, 54,
68).
Natural polymers like chitosan, gelatin, albumin, and sodium alginate have also
been investigated and used to avoid the toxicological problems associated with the use
of synthetic polymers (76, 121, 141). Recently one FDA approved drug made up of
albumin nanoparticles is Abraxane® containing paclitaxel for use in patients with
metastatic breast cancer who have failed combination therapy. Protein, peptides,
vaccines, and oligonucleotides represent an important class of biotech drugs for which
polymeric nanoparticles offer an attractive possibility.
Polymeric nanoparticles offer engineered specificity allowing them to deliver a
higher concentration of pharmaceutical agents to a desired location. But, particulate
drug carriers are subject to rapid removal from the circulation by the macrophages of
the MPS (mononuclear phagocytic system), the main obstacle in targeting various non‐
phagocytic cells of the body. Attempts have been made to develop stealth nanoparticles
carrying proteins and peptides by surface modification with a hydrophilic, flexible and
non‐ionic polymer, like poly(ethylene glycol), which has shown promising results (72,
111). In spite of numerous advantages offered by the polymeric nanoparticles due to
the availability of an extensive number of polymers, they also have limitations in terms
of their cytotoxicity, because their nanometer size range is conducive to internalization
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by cells (macrophages), and degradation inside the cell can lead to cytotoxic effects as
reported for polyester polymers.
Among all synthetic and semi‐synthetic polymers, the polyester family (i.e. PCL,
PLA, PGA, PLGA) have been extensively used because of their biocompatibility and
biodegradability properties. In particular, PLGA poly‐(lactide‐co‐glycolide) has been FDA
approved for human therapy (116). PLGA is co‐polymer of poly lactic acid (relatively
hydrophobic) and poly glycolic acid (relatively hydrophilic in nature; Fig. 1.6).
The drug is either dispersed throughout the polymer matrix in nanospheres or
enacapsulated in the hydrophobic core inside the thin polymer wall of the nanocapsule.
Drug release from PLGA particles has been shown to be biphasic, initially through
diffusion from the polymer matrix and later by a combination of diffusion and polymer
degradation (93). As polyester in nature, PLGA co‐polymer is degraded by hydrolytic
cleavage of ester bonds to lactic acid and glycolic acid. These monomers are
metabolized in the body by entering into the citric acid cycle and are removed as carbon
dioxide and water (56, 93). There are different PLGA co‐polymer compositions available
(e.g. 50:50, 65:35, 75:27, 85:15 d,l lactide/glycolide) that have progressively longer in
vivo degradation times. The choice of different polymer formulation allows this polymer
to be used as a controlled release device in different applications. This polymer has
been extensively investigated for safety and cellular toxicity in animal studies and is
being currently used in humans for resorbable sutures, bone implants and screws, and
contraceptive implants (47). Long‐term biocompatibility was demonstrated by the
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absence of any unwanted effects on intravascular administration of PLGA nanoparticles
to arterial tissue in pig and rat models of chronic restenosis (44, 94). In various studies, it
has been shown that sustained cytoplasmic delivery of many pharmacological agents
and DNA using PLGA nanoparticles resulted in desired therapeutic effects (95, 101).
Thus, PLGA nanoparticles could prove to be a useful delivery mechanism for sustained
intracellular delivery of pharmaceutical agents such peptides, DNA and other drugs with
the minimum cellular toxicity.

Dissertation Outline
This dissertation research is focused on beginning to explore the feasibility of
using pharmacological therapies to counteract the epidemic of obesity. In general, my
research is focused on identifying nutrient (e.g. fat) responsive pathways in cells
involved with the release of satiety signals and using this information to begin to
develop novel drug delivery strategies to reduce food intake. Nutrient‐induced
stimulation of enteroendocrine cells in the small intestine leads to release of hormones
(CCK and GLP‐1) that contribute to satiety. In Chapter 2, my research is focused on
mechanisms that underlie the ability of fat (fatty acids) to stimulate enteroendocrine
cell line, STC‐1. Using RT‐PCR we and others have identified rich array of fatty acid
activated GPCRs such as GPR120, GPR40, GPR41 and GPR43 in STC‐1 cells. To explore
the functional responses of fatty acids in STC‐1 cells, I used ratiometric calcium imaging
and patch clamp techniques. Further I took both pharmacological and RNA interference
approach to identify specific proteins involved in fatty acid transduction pathway in
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STC‐1 cells.
In Chapter 3, my research is focused on recording and characterization of TRPM5
ion channel activity in response to bitter tastants. Our data in Chapter 2 implicate
TRPM5 in the fat transduction pathway and in this research we explore the function of
this channel in response to a more well characterized stimulus class, bitter compounds.
Genetic studies in taste clearly demonstrate that TRPM5 is essential for sweet, bitter
and umami taste transduction. While the role of TRPM5 in bitter taste transduction is
unequivocal, bitter‐activated TRPM5 currents have never been recorded in native cells.
Moreover, at the cellular level, TRPM5 ion channels have never been shown to be
involved in bitter transduction pathway in native cells. In the present study, using
combination of whole‐cell patch clamp recording and ratiometric calcium imaging
technique I demonstrate activity of TRPM5 channel in response to bitter stimuli and
show a direct role of TRPM5 in bitter transduction pathway. Interestingly, I was able to
show that bitter activated TRPM5 channels function downstream of G proteins and PLC.
Another goal of my dissertation work was to develop and characterize
nanoparticle mediated drug delivery system for delivering pharmaceutical agents/genes
specifically to the cells (Type‐I enteroendocrine cells/STC‐1 cells) involved in control of
food intake. Chapter 4 describes strategies to fabricate nanoparticles from
biodegradable polymer PLGA (poly (D,L‐lactide‐co‐glycolide)). Next, I characterized
various physio‐chemical properties of PLGA nanoparticles. After fabrication and
characterization I performed intracellular uptake study in order to optimally delivery
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payloads inside cells. Finally, we checked the effects of internalized PLGA nanoparticles
on ion channels and signaling pathway involved in CCK release.
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Table1.1 Summary of peptide hormones that play a role in the control of food intake
(119).CCK, cholecystokinin; GLP‐1, glucagon‐like peptide‐1; PYY, peptide tyrosin‐tyrosin;
APO‐AIV, apolipoprotein AIV.
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Figure 1.1: Neuroanatomical model of pathways by which adiposity signals interact with
central autonomic system in order to control food intake (114).
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LIFESTYLE CHOICES

Eat too much; exercise too little

SOCIOECONOMIC FACTORS
Education level; food cost

METABOLIC DISORDERS

Differences in energy expenditure

GENES
Obesity linked directly to genes

Figure 1.2: The development and maintenance of obesity is influenced by genetic,
environmental and behavioral factors. Epigenetic effects, in turn, may influence each of
these factors. Not drawn to scale.
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Figure 1.3: Relationship between dietary fat intake and body mass index (BMI).
Individuals with BMI > 25 are considered overweight or obese. Taken from Bray and
Popkin [60].

46
FA

FA

Na+

GPR

R

TRPM5
PIP2

Ca++

DRK

VGCC

DAG

Gα

+++
PLCß2
IP3

+++
Ca++

IP3R3

K+

[Ca++]in

Satiety hormone secretion

Figure 1.4: Working hypothesis of fatty acid transduction in enteroendocrine cells. Fatty
acids (FA) activate G protein coupled receptors (GPR) linked to the stimulation of a
specific isoform phospholipase C (PLCß2) and the generation of two second messengers,
diacylglycerol (DAG) and inositol trisphosphate (IP3). IP3 binds to IP3 receptor type 3
(IP3R3) on the endoplasmic reticulum and releases intracellular Ca++. The rise in
intracellular Ca++ activates the membrane channel, TRPM5, whose activation further
depolarizes the cell via Na+ influx. This depolarization opens voltage‐dependent, fatty
acid‐sensitive delayed rectifying K+ (DRK) channels, whole inhibition further prolongs the
FA‐activated depolarization. This depolarization opens voltage‐gated Ca++ channels
(VGCC) leading to a Ca++ rise intracellularly and eventual release of satiety hormones.
The red X indicates that my data suggest that release from intracellular stores does not
itself directly contribute significantly to the total rise in Ca++ in enteroendocrine cells.
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Figure 1.5: Schematic of nanoparticle containing potential reagents & targeting
Moieties.

Figure 1.6: Chemical structure of PLA and PGA.
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CHAPTER 2
TRPM5 IS CRITICAL FOR LINOLEIC ACID‐INDUCED RESPONSES IN THE
ENTEROENDOCRINE CELL LINE, STC‐1 †

Abstract
Free fatty acid (FFA)‐induced stimulation of enteroendocrine cells leads to
release of the hormones, such as cholecystokinin (CCK), that contribute to satiety.
Recently, the fatty acid activated G‐protein coupled receptor, GPR120, has been shown
to mediate long chain unsaturated FFA‐induced CCK release from the enteroendocrine
cell line, STC‐1. However, the signaling pathway following activation of GPR120 that
leads to CCK release has not been defined. To explore functional responses to
unsaturated long chain FFAs in STC‐1 cells, we have used patch clamping and ratiometric
calcium imaging. The prototypical unsaturated long chain FFA stimulus, linoleic acid
elicits membrane depolarization and an intracellular calcium rise in STC‐1 cells. Linoleic
acid induced depolarization is significantly reduced when activity of G proteins and
phospholipase C (PLC) is blocked, suggesting that depolarization in response to linoleic
acid depends on the G protein‐PLC pathway. Linoleic acid ultimately leads to activation
of monovalent cation specific TRPM5 channels in STC‐1 cells. Linoleic acid induced
TRPM5 currents are significantly reduced when expression of TRPM5 or GPR120 is
knocked down using RNA interference. The latter finding suggests that linoleic acid
induced activation of TRPM5 channels is downstream of GPR120. Further, the linoleic
†
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acid induced rise in intracellular calcium is significantly reduced when expression of
TRPM5 channels are reduced using RNA interference, consistent with a role of TRPM5 in
fatty acid transduction pathway in STC‐1 cells.

Introduction
The presence of ingested fat, specifically in the form of free fatty acids (FFAs),
activates enteroendocrine cells (EECs) in the proximal small intestine which initiates a
number of physiological functions including initiating the onset of satiety, potentiating
insulin release, and delaying gastric emptying (8, 10, 15). Of its many physiological roles,
FFA‐induced onset of satiety is regarded as one of the key mediators for meal
termination. FFA‐induced satiety is mainly mediated by secretion of satiety peptides
including cholecystokinin (CCK) and glucagon‐like peptide‐1 (GLP‐1) by specialized EECs
(Type I) present in pre‐absorptive sites in the intestine (7, 8, 15, 25, 29). Interestingly,
only long chain FFAs are apparently capable of inducing CCK release in humans and in
the murine enteroendocrine Type I cell line, STC‐1 (18‐20, 24). STC‐1 cells have been
very useful as a model for chemosensory endocrine cells and provide an opportunity to
study the signal transduction pathway for FFA‐induced CCK release.
While FFAs are known to be involved in numerous physiological functions,
relatively little is known how FFAs activate cells or the specific elements of the
transduction pathway. Gilbertson et al. demonstrated the first evidence that FFAs
activate chemosensory cells (i.e. taste receptor cells; TRC) by interacting with delayed
rectifying potassium (DRK) channels (6). More recently, several additional fatty acid

50
responsive proteins have been identified that may play a role in the initiating fatty acid
transduction. These include the fatty acid binding protein, CD36 (13) and several G
protein coupled receptors (GPCRs) including GPR40, GPR41, GPR43, GPR84, and GPR120
have been identified as receptors for FFAs and shown to mediate various FFA‐induced
regulatory functions in different tissues (2, 3, 9, 11, 14, 23, 28, 30). Of particular interest
in the digestive system is GPR120, which is abundantly expressed in intestine and
functions as receptor for unsaturated long chain FFAs (10). GPR120, but not GPR40,
which has similar but not identical ligand specificity, has been shown to mediate
unsaturated long chain FFA (PUFA)‐induced release of CCK and GLP‐1 in STC‐1 cells by
increasing the intracellular calcium concentration (10, 27). Moreover, removal of
extracellular calcium and/or application of the L‐type voltage gated calcium channel
blocker nicardipine significantly reduced the long chain FFA‐induced intracellular
calcium rise and CCK secretion in STC‐1 cells (24, 27). Thus, it is reasonable to postulate
from these observations that PUFAs may depolarize STC‐1 cells by activating GPR120
receptors and this depolarization activates L‐type voltage gated calcium channels
leading to an elevation of intracellular calcium concentration and subsequent CCK
secretion. The link between GPR120 and the development of the receptor potential (i.e.
depolarization) remains unknown.
One candidate for producing the FFA‐induced receptor potential in nutrient‐
responsive cells is the transient receptor potential channel type M5 (TRPM5). TRMP5 is
a calcium‐activated, non‐selective, monovalent cation‐permeable channel that is highly
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expressed in TRCs and is required for sweet, bitter and umami taste transduction (17,
21, 22, 26, 31). TRPM5 in TRCs appears to be involved in the final step of a signaling
cascade culminates in membrane depolarization. While TRPM5 is unequivocally involved
in taste transduction, activity of TRPM5 channels has never been recorded in native cells
in response to taste stimuli. Other than TRCs, TRPM5 mRNA has been expressed in
various tissues like olfactory epithelium, lung epithelium and, importantly, in
chemosensory cells found in gut, including STC‐1 cells (1, 12, 16). While TRPM5 has been
implicated in chemosensory transduction in STC‐1 cells, it has not been studied directly
in these cells.
In present study, we show for the first time that the prototypical long chain FFA
stimulus; linoleic acid, depolarizes STC‐1 cells via activation of TRPM5. Linoleic acid
induced depolarization is significantly reduced when GDP‐β‐S and/or U73122 are used
to block G proteins and phospholipase C (PLC), respectively, suggesting that
depolarization in response to linoleic acid depends on G protein‐PLC pathway. Linoleic
acid activates sodium dependent TRPM5 currents which were significantly reduced
when siRNA specific to GPR120 is transfected in STC‐1 cells consistent with the
interpretation that TRPM5 is activated downstream of GPR120. The linoleic acid induced
intracellular calcium rise is significantly reduced when siRNA specific to TRPM5 is
transfected in STC‐1 cells.

Materials and Methods
Cell culture. The murine enteroendocrine cell line STC‐1, a generous gift from Dr.

52
D. Hanahan (University of California, San Francisco), was derived from intestinal
endocrine tumor developed in double transgenic mouse expressing insulin promoter
linked to simian virus 40 large T antigen and polyoma virus small T antigen. STC‐1 cells
were cultured using Dulbecco’s modified Eagle’s medium containing 10% (v/v) fetal
bovine serum (FBS). STC‐1 cells were plated on glass coverslips 24‐48 hours prior to
calcium imaging and electrophysiological studies.
Intracellular calcium imaging. STC‐1 cells were loaded with Fura‐2/AM (5 µM;
Molecular Probes, Eugene, OR) for 1 hour in Tyrode's with 10% pluronic acid at 37°C in
the dark. Cells were then rinsed and placed in medium for 30 minutes to allow de‐
esterification of acetoxymethyl ester group from Fura‐2. The coverslips were mounted
onto the chamber (RC‐25F, Warner Instruments, Hamden, CT), placed on an inverted
microscope (Nikon, Eclipse TS100, Japan) and perfused continuously with Tyrode's. Cells
were illuminated with a 100‐watt xenon lamp and excitation wavelengths (340/380 nm)
were delivered by a monochromator (Bentham FSM150, Intracellular Imaging Inc.,
Cincinnati, OH) at a rate of 20 ratios per minute. Fluorescence was measured by a CCD
camera (pixelFly, Cooke, MI) coupled to a microscope and controlled by imaging
software (Incyt Im2TM, Intracellular Imaging). The ratio of fluorescence (340 nm/380 nm)
was directly converted to calcium concentrations using a standard curve generated for
the imaging system using Fura‐2 calcium imaging calibration kit (Molecular Probes,
Eugene, OR). Fatty acids and other compounds were applied extracellularly with a bath
perfusion system at a flow rate of 4 ml/min permitting complete exchange of the
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extracellular solution in less than 20 seconds.
Solutions. Standard extracellular saline solution (Tyrode's) contained (in mM):
140 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose, and 10 Na pyruvate; pH 7.40
adjusted with NaOH; 310 mOsm. Sodium‐free saline (sodium free Tyrode's) contained
(in mM): 280 mannitol, 5 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose; pH 7.40 adjusted
with TrisOH; 310 mOsm (adjusted with mannitol). 60 mM Na+ Tyrode's contained (in
mM): 50 NaCl, 180 mannitol, 5 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose, 10 Na
pyruvate. 10 mM Na+ Tyrode's contained (in mM): 280 mannitol, 5 KCl, 1 CaCl2, 1 MgCl2,
10 HEPES, 10 glucose, 10 Na pyruvate. Calcium free saline (calcium free Tyrode's)
contained (in mM): 140 NaCl, 5 KCl, 1 EGTA, 1 MgCl2, 10 HEPES, 10 glucose, and 10 Na
pyruvate; pH 7.40 adjusted with NaOH; 310 mOsm. The K+ based intracellular solution
was used for measurement of membrane potential contained (in mM): 140 K gluconate,
1 CaCl2, 2 MgCl2, 10 HEPES, 11 EGTA, 3 ATP, and 0.5 GTP; pH 7.2 adjusted with KOH;
310mOsm. A Cs+ based intracellular solution was used for recording TRPM5 currents and
contained (in mM): 140 Cs acetate, 1 CaCl2, 2 MgCl2, 10 HEPES, 11 EGTA, 3 ATP, and 0.5
GTP; pH 7.2 adjusted with TrisOH; 310 mOsm. U‐73122, an inhibitor of PLC, U‐73343,
the inactive analog of U‐73122, and bombesin were purchased from Sigma (St. Louis,
MO). GDP‐β‐S, an inhibitor of G protein activation was obtained from EMD Biosciences
(La Jolla, CA). The linoleic acid stock was made in 100 percent ethanol and working
solutions were made from stock solutions immediately prior to use.
Electrophysiological recording and analysis. We performed whole‐cell patch
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clamp recording to measure membrane potential (current clamp mode) and/or to
record FFA‐induced currents (voltage clamp mode) in STC‐1 cells with an Axopatch‐200B
amplifier (Molecular Devices, Sunnyvale, CA). Patch pipettes were fabricated from
borosilicate glass on a Flaming‐Brown micropipette puller (model P‐97; Sutter
Instrument, Novato, Ca) and subsequently fire polished on a microforge (model MF‐9.
Narishige) to a resistance of 5‐8 MΩ. Commands were delivered and data were recorded
using pCLAMP software (v. 10, Molecular Devices, Sunnyvale, CA) interfaced to an
Axopatch‐200B amplifier with a DigiData 1322A analog‐to‐digital board. Data were
filtered online at 1 kHz and sampled at 2‐4 kHz.
Membrane potential measurement. The membrane potential (VM) of STC‐1 cells
was recorded continuously before, during and after fatty acid (linoleic acid) application
using the current clamp mode of the amplifier while holding the cell at its zero current
level (i.e. at rest). For recording FFA‐induced changes in membrane potential, linoleic
acid was applied by bath application in most cases. In other experiments, rapid, focal
application of fatty acids was used and produced similar results. To determine the ionic
dependence of FFA‐induced changes in membrane potential, VM was recorded in three
different extracellular solutions including Tyrode's, sodium free Tyrode's and calcium
free Tyrode's.
TRPM5 current recording. FFA‐induced TRPM5 currents in STC‐1 cells were
recorded using the voltage clamp mode. Typical inward currents were recorded at a
holding potential of ‐100 mV. Fatty acid was applied focally from a pipette positioned
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near the cell and delivered by a PicoSpritzer III (Parker Hannifin Corp, Cleveland, OH)
controlled by the data acquisition and analysis software. Ramp protocols from ‐100 mV
to +100 mV (500 ms duration) were used to generate instantaneous current‐voltage (I‐
V) relationship of linoleic acid induced TRPM5 current in various solutions.
siRNA construction and transfection. For small interfering RNA experiments, we
used Silencer® pre‐designed siRNA and Silencer® select pre‐designed siRNA targeted
against GPR120 and TRPM5, respectively (Ambion, Austin TX) according to
manufacturer's directions. As a negative control, we used the Silencer® control siRNA kit
(Ambion, Austin TX). The concentration of siRNA used for transfection was 25‐200 nM.
STC‐1 cells were reverse transfected with siRNA complexes using LipofectamineTM 2000
(Invitrogen, Carlsbad CA) transfection reagent 24‐48 hours prior performing functional
assays or performing quantitative PCR.
Quantitative RT PCR. RNA was isolated using Tri Reagent® (Molecular Research
Center Inc., Cincinnati, OH) according to manufacturer’s instructions. For real‐time
quantification of mRNA, we used two‐tube RT‐PCR. First‐strand cDNA was synthesized
using an iScript kit from Bio‐Rad (Hercules, CA). The RNA concentration was 50 ng per 20
µl reaction volume. The SmartCycler™ from Cepheid (Sunnyvale CA) was used to follow
the PCR reaction in real time. The HotMaster Taq DNA polymerase kit (5 Prime inc.,
Gaithersburg, MD ) was used for the PCR reaction (final concentration: 1X reaction
buffer, 5 mM Mg2+, 200 µM dNTPs, 300‐900 nM forward and reverse primers (for
GPR120), 60 nM for GAPDH and 1.25 U/µl HotMaster Taq). Two µl cDNA per reaction
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was amplified using a 2‐step PCR (6 s denaturation, 60 s annealing and extension). We
used a TaqMan® detection system and primer pairs for the target sequences were
multiplexed with the primer pairs for the housekeeping gene, GAPDH, for comparison of
expression levels in STC‐1 cells. Primers and probes for GPR120 (sense/antisense; 5’‐
CTGCACATTGGATTGGC‐3’/5’‐TCTGGTGGCTCTCGGAGTAT‐3’; 624 ‐640/783‐802) and
GAPDH (sense/antisense;5’‐TGCACCACCAACTGCTTAG‐3’/5’‐GGATGCAGGGATGATGTTC‐
3’; 487‐496/636‐654) were designed using Oligo 6.0 Primer Analysis Software
(Molecular

Biology

Insights,

Inc.,

Cascade

CO).

GPR120

probe

(5’‐

CTCTTCCGCGAGGCTTTCGTGATCTGT‐3’; 738‐764) was labeled at the 5’‐end with FAM as
the reporter dye and BHQ‐1 at the 3’‐end as the quencher dye. The GAPDH probe (5’‐
ATCACGCCACAGCTTTCCAGAGGG‐3’; 595‐618) was labeled with ROX as the reporter and
BHQ‐2 as the quencher (Integrated DNA Technologies, Coralville IA). For detection of
TRPM5, a predesigned Taqman® Gene Expression Assay (Applied Biosystems, Foster City
CA) was used.
Statistical analysis. The significant effects of all the treatments were determined
by unpaired Student’s t‐test (α=0.05) compared with their controls as described in the
text. Data are presented as mean + SEM, unless otherwise indicated.

Results
Linoleic acid depolarizes and elicits a rise in intracellular calcium in STC‐1 cells.
In the present study, we have used ratiometric calcium imaging and patch clamp
recording to explore signaling pathway of PUFA‐induced hormone secretion in STC‐1
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cells. As a first approach we used the prototypical PUFA stimulus, linoleic acid (30 µM),
to elicit changes in intracellular calcium measured using the ratiometric dye Fura‐2‐AM
imaged with a high speed ratiometric calcium imaging system (InCyt2‐IM; Intracellular
Imaging, Inc., Cincinnati OH). Similar to the responses shown by others (10), linoleic acid
(30 µM) elicits a robust and reversible increase in intracellular calcium (349.0 ± 10.7 nM;
n=114; Fig. 2.1A, 2.1D) in STC‐1 cells.
In order to explore the effect of linoleic acid (30 µM) on membrane potential of
STC‐1 cells, patch clamp recording was performed in the whole‐cell current clamp
configuration. STC‐1 cells were held at zero current level to determine the resting
membrane potential. In 13 cells the recorded average resting membrane potential was ‐
60.0 ± 2.5 mV. Linoleic acid (30 µM) applied by bath perfusion elicited large and
reversible depolarizations of 68.3 ± 2.4 mV (n=13; Fig. 2.1E). Importantly, the time
courses of both the linoleic acid induced calcium rise (Fig. 2.1A) and membrane
depolarization (Fig. 2.1E) were comparable using these two approaches.
Next we carried out a series of imaging experiments to investigate the
dependence of the linoleic acid induced changes in intracellular calcium on extracellular
sodium, extracellular calcium and intracellular calcium. In the absence of extracellular
calcium, the linoleic acid induced rise in intracellular calcium is significantly reduced
(55.0 ± 5.3 nM; p<0.001; n=56; Fig. 2.1B, 2.1D). This significant reduction in intracellular
calcium rise in the absence of extracellular calcium is similar to that shown by others
(24). Our data are consistent with the interpretation that linoleic acid also causes
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release of calcium from intracellular stores. Interestingly, removal of extracellular
sodium caused a significant decrease in the linoleic acid (30 µM) induced rise in
intracellular calcium (95.1 ± 10.9 nM; n=58; Fig. 2.1C, 2.1D). Thus, both intracellular and
extracellular increases in calcium appear to contribute to the fatty acid responses in
STC‐1 cells.
To determine if monovalent cation entry was contributing to the membrane
depolarization seen in the electrophysiological experiments, we performed a series of
experiments in the absence of extracellular sodium. In order to examine if the linoleic
acid induced depolarization was dependent on extracellular sodium and/or calcium, we
did patch clamp recording on STC‐1 cells. Removal of extracellular calcium ions did not
alter the linoleic acid (30 µM) induced depolarization compared to control ([Ca2+]out=0:
68.4 ± 1.7 mV, n=7; control: 68.3 ± 2.4 mV, n=12; Fig. 2.1F, 2.1H). On the other hand,
when extracellular sodium was removed, the linoleic acid induced depolarization was
significantly reduced (9.2 ± 3.3 mV; n=6; p<0.001; Fig. 2.1G, 2.1H). These results may
indicate that sodium entry is necessary for depolarization in STC‐1 cells upon linoleic
acid application and that calcium influx is downstream of sodium entry (depolarization).
Involvement of G proteins and phospholipase C in linoleic acid induced
depolarization. GPR120, a long chain PUFA activated GPCR, has been shown to play an
instrumental role in the PUFA‐induced calcium rise and eventually hormone (GLP‐1,
CCK) release from STC‐1 cells (10, 27). In order to confirm the role of G proteins in the
signaling pathway, we examined the effect of blocking G protein activation with the
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reversible blocker GDP‐β‐S (1 mM) on linoleic acid induced depolarization. In
electrophysiological experiments, GDP‐β‐S was included in the intracellular solution and
membrane potential was recorded 2‐3 minutes after achieving the whole cell
configuration. Linoleic acid induced depolarization was significantly reduced in presence
of GDP‐β‐S (6.9 ± 2.6 mV; n=8; p<0.001; Fig. 2.2A, 2.2D, 2.2E) compared to control (68.3
± 2.4 mV; n=12; Fig. 2.2A, 2.2E) STC‐1 cells. Next, we determined the involvement of PLC
in linoleic acid signaling in STC‐1 cells. Depolarization in response to linoleic acid is
significantly reduced in presence of the PLC blocker U73122 (3 µM) (4.2 ± 4.2 mV; n=5;
p<0.001; Fig. 2.2B, 2.2E) but is not affected by treatment with the inactive analog
U73343 (3 µM) (57.2 ± 6.7 mV; n=5; n.s.; Fig. 2.2C, 2.2E) when compared with the
control. To determine the role of PLC in the intracellular calcium rise initiated in
response to linoleic acid using calcium imaging, STC‐1 cells were pretreated with 3‐5 µM
U73122 for 30 minutes. STC‐1 cells showed profoundly reduced intracellular calcium rise
in response to linoleic acid (data not shown).
Linoleic acid activates sodium dependent inward currents in STC‐1 cells. In
whole‐cell voltage clamp experiments (Vh= ‐100 mV), rapid and focal application of 30
µM linoleic acid induced large amplitude inward currents in STC‐1 cells (2010.5 + 379.3
pA; n=16; Fig. 2.3A). In separate current clamp experiments, we found that rapid and
focal application of 30 µM linoleic acid depolarized the cell (Fig. 2.3A inset) with a similar
time course. Removal of extracellular sodium abolished inward currents in response to
linoleic acid (48.6 + 15.2 pA; n=10; p<0.001; Fig. 2.3B, 2.3C). Removal of extracellular
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calcium ions did not alter the inward current in response to linoleic acid (data not
shown). Next we did a series of experiments to investigate permeability properties of
linoleic acid induced inward currents. In standard experimental conditions (i.e. total
monovalent cation concentrations equal on both sides on the membrane), the current‐
voltage relationship of linoleic acid induced currents yields a reversal potential of ≈ 0 mV
(Fig. 2.3D), consistent with the interpretation that linoleic acid activates a non‐selective
cation permeable pathway. Under these conditions (Tyrode's outside; cesium‐based
intracellular solution), the inward current is carried by sodium and the outward current
is carried by cesium ions. Consistent with this conclusion, changes in extracellular
sodium ions led to predictable changes in the reversal potential of linoleic acid induced
currents that were closely predicted by Goldman‐Hodgkin‐Katz (GHK) equation for
sodium, potassium and cesium‐permeable conductance (Fig. 2.3D, 2.3E), assuming that
the relative permeability of all three ions is equal). Further, partial substitution of
intracellular cesium ions with mannitol shifted the reversal potential of linoleic acid
induced currents shifted the reversal potential in a predictable manner (data not
shown).
TRPM5 mediates linoleic acid induced calcium signaling. The

calcium‐

activated, monovalent cation selective channel, TRPM5 has been shown to play a critical
role in taste transduction pathway of sweet, bitter and umami stimuli where it
apparently acts downstream of taste GPCR activation (17, 31). However, there have
been no detailed reports that have shown the activation of TRPM5‐like currents in
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native taste cells. TRPM5, as well as GPCR taste receptors and other G protein signaling
elements, are expressed in STC‐1 cells (5, 17, 22). Based on our results that linoleic acid
activated currents in STC‐1 cells are primarily monovalent cation selective, we
investigated specific involvement of TRPM5 ion channels in linoleic acid‐activated
inward current by using the TRPM5 channel blocker triphenylphosphine oxide (TPPO)
(4). In whole‐cell voltage clamp experiments, we compared linoleic acid‐induced inward
currents in control STC‐1 cells and in TPPO treated (100 µM, 2 min pre‐treatment) STC‐1
cells. TPPO treatment significantly reduced linoleic acid induced inward current (374.3 +
84.4 pA; n=9; p=0.04; Fig. 2.4A, 2.4B) when compared to untreated STC‐1 cells (1631.5 +
521 pA; n=10; Fig. 2.4A, 2.4B). To confirm that TPPO was acting at TRPM5, we examined
effect of TPPO on currents elicited by the bitter stimulus, denatonium benzoate (DB,
10mM). TPPO (162 + 32.6 pA; n=6; p<0.001; Fig. 2.4B) significantly reduced denatonium
benzoate induced inward currents when compared to control DB responses (1176.6 +
102.6 pA; n=6; Fig. 2.4B) in STC‐1 cells. Interestingly, TPPO mediated inhibition of inward
currents in response to both linoleic acid and denatonium benzoate is very similar (Fig.
2.4B).
In order to further validate the involvement of TRPM5 in the linoleic acid
induced activation of STC‐1 cells, we transfected STC‐1 cells either with siRNA specific to
TRPM5 (siTRPM5) or with a nonsense sequence (control, siNEG) and examined inward
currents in response to 30 µM linoleic acid. Inward currents in response to linoleic acid
were significantly reduced in siTRPM5 treated cells (346.9 + 75.0 pA, n=10; p<0.001; Fig.
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2.4D, 2.4E) compared to siNEG treated cells (1925.7 + 285.1 pA, n=18; Fig. 2.4C, 2.4E).
There was no significant difference found in the magnitude of inward currents in
response to 30 µM linoleic acid in siNEG treated and untransfected STC‐1 cells (n=16;
Fig. 2.4E). Quantitative real time PCR in STC‐1 cells confirmed that siTRPM5 treatment
significantly (p=0.038) reduced TRPM5 mRNA by about 80% compared to siNEG treated
cells (Fig. 2.4I). There was no statistical difference found in TRPM5 mRNA levels in siNEG
treated and untransfected STC‐1 cells.
Next, we examined the effect of TRPM5 knockdown on linoleic acid stimulated
calcium signaling since we hypothesized, based upon our data, that much of the rise in
intracellular calcium was downstream of TRPM5 activation. The linoleic acid induced rise
in intracellular calcium concentration was significantly reduced in siTRPM5 treated STC‐
1 cells (95.0 + 13.8 nM; n=71; P<0.001; Fig. 2.4G, 2.4H) when compared to siNEG treated
STC‐1 cells (355.0 + 31.2 nM; n=84; Fig. 2.4F, 2.4H). However, intracellular calcium rise in
response to bombesin (2 µM), which does not involve activation of TRPM5, is unaffected
in all the examined cells (siNEG, 348.7 + 20.7 nM, n=84; siTRPM5, 318.0 + 16.2 nM,
n=71, n.s.; Fig. 2.4F, 2.4G, 2.4H).
TRPM5 is activated downstream of GPR120. In STC‐1 cells, GPR120, and
apparently not GPR40, mediates PUFA induced intracellular calcium rise (10). Next, we
investigated whether activation of TRPM5 is downstream of activation of GPR120
receptors in response to linoleic acid. We transfected STC‐1 cells either with siRNA
specific to GPR120 (siGPR120) or nonsense siRNA (siNEG) and compared the magnitude
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of linoleic acid activated TRPM5 currents. TRPM5 currents in response to linoleic acid
were significantly reduced in siGPR120 treated STC‐1 cells (562.1 + 77.8 pA; n=17;
p<0.05; Fig. 2.5B, 2.5C) when compared to siNEG treated STC‐1 cells (2025.3 + 337.2 pA;
n=15; Fig. 2.5A, 2.5C). We did not observe any significant difference in linoleic acid
induced TRPM5 currents between untransfected cells (2010.4 + 379.3 pA; n=16) and
siNEG treated (2025.3 + 337.2 pA; n=15) STC‐1 cells. As shown in Figure 2.5D, siGPR120
treatment significantly (p<0.05) reduced GPR120 mRNA by about 90% compared to
siNEG treated cells. There was no statistical difference found between GPR120 mRNA
levels in siNEG treated and untransfected STC‐1 cells. Further, we examined effect of
GPR120 knockdown on linoleic acid induced intracellular calcium changes since the rise
in intracellular calcium is an essential signal for initiating satiety hormone secretion in
STC‐1 cells. The linoleic acid (30 µM)‐induced rise in intracellular calcium rise is
significantly reduced in siGPR120 treated STC‐1 cells (127.2 + 17.0 nM; n=88; p<0.05;
Fig. 2.5F, 2.5G) when compared to siNEG treated STC‐1 cells (355.0 + 31.2 nM; n=84; Fig.
2.5E, 2.5G), an effect seen by others (10). The bombesin‐induced change in intracellular
calcium rise is unaffected by siGPR120 treatment in all examined cells (siNEG, 348.7 +
20.7 nM, n=84; siGPR120, 306.3 + 15.7 nM, n=88, p>0.05; Fig. 2.5E, 2.5F, 2.5G) showing
that responsiveness in other pathways remained intact.

Discussion
PUFAs stimulate STC‐1 cells and release satiety hormones like CCK by activating
the G protein coupled receptor GPR120 and elevating intracellular calcium
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concentrations (27). Several groups have shown that intracellular calcium rise is
mediated largely by calcium influx through voltage gated calcium channels and is
necessary and sufficient step for FFA‐induced satiety hormone release (20, 27).
However, the details of the intracellular signaling cascade initiated by PUFAs in STC‐1
cells that culminate in CCK release have not been studied in great depth. In the present
manuscript we have attempted to unravel the PUFA initiated signaling cascade that
leads to the intracellular calcium rise necessary for CCK secretion in STC‐1 cells. We
show that TRPM5 provides the basis for the fatty acid induced receptor potential
necessary for the opening of voltage‐gated calcium channels and provide some of the
first data on TRPM5 currents activated by ligands in native cells. In the initial calcium
imaging experiments in STC‐1 cells, we found that removal of extracellular sodium ions
and extracellular calcium ions significantly reduced the linoleic acid (30 µM)‐induced
intracellular calcium rise. This led us to conclude that sodium entry is required for the
linoleic acid induced rise in intracellular calcium. Subsequently, we showed that linoleic
acid depolarized STC‐1 cells and that this depolarization was strictly dependent on
extracellular sodium ions but not on extracellular calcium ions. These results in
conjunction with our calcium imaging results demonstrate that the linoleic acid‐
mediated depolarization of STC‐1 cells is dependent upon sodium entry and provides
the stimulus (i.e. depolarization) required for activation of voltage gated calcium
channels, which, in turn, allows influx of calcium ions and hormone release. Our data
showed that linoleic acid‐induced depolarization is profoundly reduced by blocking G
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protein activation and PLC activity by GDP‐β‐S and U73122, respectively, thus
confirming the role of GPCRs in PUFA signaling in STC‐1 cells.
In the present study we also showed that linoleic acid initiates transient receptor
potential (TRP)‐like rapid inward currents in STC‐1 cells. Linoleic acid‐induced inward
currents were abolished upon removal of extracellular sodium ions, which is consistent
with dependence of linoleic acid induced depolarization and intracellular calcium rise on
extracellular sodium ions. Linoleic acid induced inward currents were not affected by
altering extracellular calcium ions. Ion substitution studies confirmed that the linoleic
acid induced currents were carried largely, if not exclusively, by monovalent cations as
the reversal potential for this current was closely predicted by the GHK equation based
upon the assumption that all monovalent cations were roughly equally permeable (Fig.
2.3D).
STC‐1 cells express multiple bitter‐activated GPCRs (T2Rs) and signaling
components identified in Type II taste receptor cells including alpha gustducin, PLC‐ß2
and TRPM5 (5). TRPM5, an ion channel found in chemosensory cells, has been shown to
play instrumental role in bitter, sweet and umami taste transduction (21, 26, 31). From
heterologous expression studies in HEK cells, TRPM5 was shown to be activated by
calcium ions and is largely selective for monovalent cations (17, 22). While the role of
TRPM5 in bitter taste transduction is unequivocal, TRPM5 currents in response to bitter
compounds have never been recorded in native cells. Our results showed for the first
time that application of a bitter compound, denatonium benzoate, activated
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extracellular sodium dependent inward currents (TRPM5). Because the linoleic acid
induced TRP‐like inward currents we recorded were selective for monovalent cations,
we investigated the possibility of TRPM5 involvement in linoleic acid induced signaling in
STC‐1 cells. TPPO, the specific antagonist for TRPM5 (4), significantly reduced linoleic
acid induced and, importantly, denatonium benzoate induced inward currents. We saw
very similar level of inhibition of linoleic acid induced and denatonium benzoate induced
inward currents upon application of TPPO. These findings suggested that linoleic acid
may also be activating TRPM5 channel to allow the entry of sodium ions. Additional
verification came from our studies using RNA interference assays. Transfection of siRNA
specific to TRPM5 in STC‐1 cells showed diminished inward current as well as a reduced
intracellular calcium rise in response to linoleic acid. These findings prove conclusively
the involvement of TRPM5 in linoleic acid initiated signaling in STC‐1 cells.
Knocking down the expression of GPR120 by RNA interference also significantly
reduced linoleic acid‐induced TRPM5 currents. These results strongly implicate that
TRPM5 is activated downstream of GPR120 which is also supported by depolarization
experiments where linoleic acid induced depolarization is profoundly inhibited when
G‐proteins and PLC activity is blocked. Finally, our results confirm and support the
previous findings about involvement of GPR120 in linoleic acid‐induced intracellular
calcium rise (10). Taken together, our findings suggest that linoleic acid (PUFA) induces a
rise in intracellular calcium in STC‐1 cells that leads to CCK release and appears to
involve GPR120, G proteins, PLC, sodium influx through TRPM5 (necessary for
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depolarization) and calcium influx via VGCC (activated by depolarization), as shown
schematically in Figure 2.6.
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Figure 2.1: Linoleic acid (LA) induced intracellular calcium rise is dependent on [Na+]out
and [Calcium]out. Linoleic acid depolarizes STC‐1 cells and depolarization is dependent on
[Na+]out but not on [Calcium]out. Bath application of linoleic acid (30 µM) induces
increase in intracellular calcium concentration in STC‐1 cells (A). Linoleic acid (30 µM)
induced rise in intracellular calcium concentration in absence of [Calcium]out (B) and
[Na+]out (C). (D) Mean responses (rise in [Calcium]in) + SEM of linoleic acid (30 µM) in
Tyrode's (control), calcium free Tyrode's and Sodium free Tyrode's. Bath application of
linoleic acid (30 µM) induces depolarization in STC‐1 cells (E). Cells were held at 0
current level (e.g., at its resting potential). Linoleic acid (30 µM) induced depolarization
in absence of [Calcium]out (F) and [Na+]out (G). (H) Mean responses (depolarization) +
SEM of linoleic acid (30 µM) in Tyrode's, Calcium free Tyrodes and Sodium free Tyrode's.
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Figure 2.2: Current clamp studies in STC‐1 cells held at their zero current level showing
that depolarization in response to linoleic acid (30 µM) is greatly reduced upon blocking
activity of G proteins and PLC. Linoleic acid (30 µM) induced depolarization in control
(A), U73122 (3 μM) treated (B) and in U73343 (3 μM, the inactive analog of U73122)
treated (C) GDP‐β‐S (1 mM) treated (D), STC‐1 cells. (E) Mean responses + SEM of 10
mM DB in control conditions, GDP‐β‐S treatment, U73122 & U73343 treatments in STC‐
1 cells.
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Figure 2.3: Rapid and focal application of linoleic acid (30 µM) elicited monovalent
cation permeable currents. Linoleic acid (30 µM) induced inward currents (Vm = ‐100
mV) in Tyrode’s (A) and Sodium free Tyrode's (B). Inset in (A) shows that rapid and focal
application of linoleic acid induces depolarization with time course similar to the
activation of inward currents. (C) Mean responses (inward currents) + SEM of linoleic
acid (30 µM) in Tyrode's and Sodium free Tyrode's. D) Current‐voltage relationship of
linoleic acid (30 µM) induced currents at 10, 60 &140 mM [Na+]out. (E) Comparison
between theoretical and measured reversal potentials + SEM of linoleic acid (30 µM)
induced currents at extracellular sodium concentrations of 10, 60 & 140 mM. Reversal
potentials shown were corrected for liquid junction potential.
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Figure 2.4: Linoleic acid (30 µM) induced responses are mediated by TRPM5 channels.
(A) Linoleic acid (30 µM) induced inward currents in presence of the TRPM5 antagonist,
TPPO (100 µM). (B) Mean responses (inward currents) + SEM of linoleic acid (30 µM)
and DB (10 mM) in control conditions and TPPO (100 μM) treatment. Linoleic acid (30
µM) induced inward currents in siNEG treated (C) and in siTRPM5 treated (D) STC‐1
cells. E) Mean responses (relative inward current to untransfected cells) + SEM of
linoleic acid (30 µM) in siNEG treated and siTRPM5‐treated STC‐1 cells. Linoleic acid (30
µM) and bombesin (2 µM) induced intracellular calcium rise in siNEG treated (F) and in
siTRPM5 treated (G) STC‐1 cells. (H) Mean responses (rise in [Calcium]in) + SEM of
linoleic acid (30 µM) and bombesin (2 µM) in siNEG treated and siTRPM5‐treated STC‐1
cells. (I) Relative expression of TRPM5 mRNA in siTRPM5 transfected compared to siNEG
transfected STC‐1 cells assayed by Q‐PCR.
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Fig. 2.5: Linoleic acid induced activation of TRPM5 channels is downstream of GPR120.
Linoleic acid (30 µM) induced inward currents in siNEG treated (A) and in siGPR120
treated (B) STC‐1 cells. (C) Mean responses (relative inward current to untransfected
cells) + SEM of linoleic acid (30 µM) in siNEG treated and siGPR120 treated STC‐1 cells.
(D) Relative expression of GPR120 mRNA in siGPR120 transfected compared to siNEG
transfected STC‐1 cells assayed by Q‐PCR. Linoleic acid (30 µM) and bombesin (2 µM)
induced intracellular calcium rise in siNEG treated (E) and in siGPR120 treated (F) STC‐1
cells. (G) Mean responses (rise in [Calcium]in) + SEM of linoleic acid (30 µM) and
bombesin (2 µM) in siNEG treated and siGPR120 treated STC‐1 cells.
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Fig. 2.6: A model showing linoleic acid transduction pathway in STC‐1 cells. Fatty acids
(FA) bind and activate G protein coupled receptors (GPCR) linked to the stimulation of a
specific isoform of phospholipase C (PLCß2) and the generation of two second
messengers, diacylglycerol (DAG) and inositol trisphosphate (IP3). IP3 binds to IP3
receptors (IP3R) on the endoplasmic reticulum and releases intracellular calcium. The
depletion of intracellular calcium stores activates a monovalent cation channel, TRPM5,
whose activation may further depolarize the cell via cation influx. This depolarization
opens voltage‐gated calcium channels (VGCC) leading to an intracellular calcium rise and
eventual release of satiety hormones like GLP‐1 and CCK.
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CHAPTER 3
DIRECT EVIDENCE OF THE ROLE OF TRPM5 IN BITTER TRANSDUCTION IN THE
ENTEROENDOCRINE CELL LINE, STC‐1 †

Abstract
Enteroendocrine cells (EECs) in the gastrointestinal (GI) tract have been shown to
express members of the bitter (T2R) taste receptor family and to release peptides like
CCK in response to bitter stimuli. Moreover, EECs express many of the signaling
components identified in Type II taste receptor cells including alpha gustducin, PLC‐ß2
and TRPM5. While the role of TRPM5 in bitter taste transduction is unequivocal, bitter‐
activated TRPM5 currents have never been recorded in native cells. In the current study,
we have used the enteroendocrine cell line STC‐1 to validate the proposed bitter
transduction pathway. To explore functional responses to bitter compounds in STC‐1
cells, we have used patch clamping and ratiometric calcium imaging. Structurally diverse
bitter compounds denatonium benzoate (DB) and phenylthiocarbamide (PTC)
depolarized STC‐1 cells and this depolarization was significantly reduced in absence of
extracellular sodium ions. DB and PTC also elicited rapid, Na+ dependent inward currents
at ‐100 mV. Ion substitution experiments revealed that these DB‐induced currents were
carried by monovalent cations in non‐selective manner. DB‐induced inward currents
were greatly reduced when upstream proteins like G proteins and PLC are blocked with
GDP‐ß‐S and U73122, respectively, implying that these inward currents are activated
†
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downstream of G proteins and PLC. DB‐induced inward currents were inhibited by the
TRPM5 blocker, triphenylphosphine oxide (TPPO, 20 µM) and were significantly reduced
when expression of TRPM5 was knocked down using RNA interference. These results
are consistent with a role of TRPM5 in bitter transduction. Consistent with these
electrophysiological experiments, similar results were found using Fura‐2 based calcium
imaging to characterize the role of TRPM5 in the generation of bitter‐induced changes in
intracellular calcium in EECs.

Introduction
Human and animals can perceive five primary taste modalities: bitter, sweet,
umami, salty, and sour (18, 20, 33). In contrast to salty, sweet and umami taste
modalities which detect subsets of nutritive compounds, naturally occurring toxins taste
bitter and most animals and humans display aversive behavior to these compounds (13).
Thus, the sense of bitter taste has been thought to play a very important role by
providing a central warning signal against the ingestion of harmful substances (14).
Various bitter compounds activate one or more members of a family of approximately
30 different G protein‐coupled receptors (GPCRs) known as T2Rs (1, 7, 22). It is generally
believed, that these T2Rs are expressed in a subpopulation of taste receptor cells, which
are separate from those transducing the responses of other taste modalities (1). Several
ingenious knockout and expression strategies in mice suggest that T2Rs are necessary
and sufficient for bitter taste perception (24). Various mechanisms for taste
transduction have been proposed but recent breakthroughs suggest that sweet, bitter
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and umami tastants use a common 2nd messenger signaling to activate taste receptor
cells (6, 8, 17, 31). According to this model for bitter signaling, ligand binding to T2R
GPCRs activates the ß2 isoform of phospholipase C (PLCβ2) via heterotrimeric
G‐proteins, activated PLCβ2 hydrolyzes phosphotidylinositol 4,5–bisphophate (PIP2) to
generate diacylglycerol (DAG) and inositol 3,4,5 triphosphate (IP3), IP3 activates IP3
receptors on the endoplasmic reticulum to elicit a transient rise in intracellular calcium
concentration (3, 16, 19, 23, 29, 32, 36). Recently, TRPM5, a member of the melastatin
group of transient receptor potential (TRP) ion channels has been found to be highly
expressed in taste receptor cells and identified as a key component of bitter and sweet
taste transduction (26, 36). Mice lacking TRPM5 have severe defects in tasting
physiological concentrations of bitter and sweet compounds (10, 36). TRPM5 is non‐
selective, monovalent cation permeable ion channel (15, 21, 27). Studies in both
heterologous expression systems and in taste receptor cells reveal that TRPM5 appears
to be directly activated by intracellular calcium ions providing a link between the
upstream IP3‐mediated release of calcium ions from intracellular stores and changes in
membrane potential (37). While the role of TRPM5 in bitter taste transduction is
unequivocal, bitter‐activated TRPM5 currents have never been recorded in intact, native
cells. Moreover, at the cellular level, TRPM5 ion channels have never been shown to be
involved in bitter transduction pathway in native cells. In present study, we are using
the mouse enteroendocrine cell line STC‐1 as a model system to demonstrate activity of
TRPM5 channels in response to bitter stimuli and to verify a direct role of TRPM5 in the
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bitter transduction pathway.
STC‐1 cells have been shown to express members of the bitter (T2R) taste
receptor family (34, 35) and to release satiety hormones like cholecystokinin (CCK) in
response to bitter stimuli (9), suggesting the probable role of gut in initiation of
protective behavior (vomiting and avoidance behavior) against ingestion of potentially
harmful substances. Moreover, STC‐1 cells express all the signaling components
identified in taste receptor cells including alpha gustducin, PLC‐ß2 and TRPM5 (9, 30,
34). In the present study, we show that two bitter stimuli, denatonium benzoate (DB)
and phenylthiocarbamide (PTC) induce G protein and PLC dependent TRPM5 currents in
STC‐1 cells. Further, we attempted to examine permeability properties of bitter
activated TRPM5 channels in STC‐1 cells. This report presents, to our knowledge, the
first demonstration of the direct involvement of TRPM5 ion channels in bitter
transduction pathways in native chemosensory cells.

Materials and Methods
Cell culture. The murine enteroendocrine cell line, STC‐1, was a generous gift
from Dr. D. Hanahan (University of California, San Francisco). The STC‐1 cell line was
derived from intestinal endocrine tumor developed in double transgenic mouse
expressing insulin promoter linked to simian virus 40 large T antigen and polyoma virus
small T antigen. STC‐1 cells were cultured using Dulbecco’s modified Eagle’s medium
containing 10% (v/v) fetal bovine serum (FBS). STC‐1 cells were plated onto glass
coverslips 24‐48 hours prior to calcium imaging and electrophysiological studies.
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Intracellular calcium imaging. STC‐1 cells were loaded with Fura‐2/AM (5 µM;
Molecular Probes, Eugene, OR) for 1 hour in Tyrode's with 10% pluronic acid at 37°C in
the dark. Cells were then rinsed and placed in media for 30 minutes to allow
deesterification of acetoxymethyl ester group from Fura‐2. The coverslips were
mounted onto the chamber (RC‐25F, Warner Instruments, Hamden, CT), placed on an
inverted microscope (Nikon, Eclipse TS100, Japan) and perfused continuously with
Tyrode's. Cells were illuminated with a 100‐watt xenon lamp and excitation wavelengths
(340/380 nm) were delivered by a monochromator (Bentham FSM150, Intracellular
Imaging Inc., Cincinnati, OH) at a rate of 20 ratio pairs per minute. Fluorescence was
measured by a CCD camera (PixelFly, Cooke, MI) coupled to a microscope and controlled
by imaging software (Incyt Im2TM, Intracellular Imaging). The ratio of fluorescence (340
nm/380 nm) was directly converted to calcium concentrations using a standard curve
generated for the imaging system using Fura‐2 calcium imaging calibration kit
(Molecular Probes, Eugene, OR). Bitter compounds (DB and PTC) were applied with a
bath perfusion system at a flow rate of 4 ml/min permitting complete exchange of the
extracellular solution in less than 20 seconds.
Solutions. Standard extracellular saline solution (Tyrode's) contained (in mM):
140 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose, and 10 Na pyruvate; pH 7.40
adjusted with NaOH; osmolarity 310 adjusted using NaCl. Sodium free saline (sodium
free Tyrode's) contained (in mM): 280 mannitol, 5 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, 10
glucose; pH 7.40 adjusted with TrisOH; osmolarity 310 adjusted with mannitol. 60 mM
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Na+ Tyrode's contained (in mM): 50 NaCl, 180 mannitol, 5 KCl, 1 CaCl2, 1 MgCl2, 10
HEPES, 10 glucose, 10 Na pyruvate. 10 mM Na+ Tyrode's contained (in mM): 280
mannitol, 5 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose, 10 Na pyruvate. Calcium free
saline (calcium free Tyrode's) contained (in mM): 140 NaCl, 5 KCl, 1 EGTA, 1 MgCl2, 10
HEPES, 10 glucose, and 10 Na pyruvate; pH 7.40 adjusted with NaOH; osmolarity 310
adjusted with NaCl. K+ based intracellular solution was used for measurement of
membrane potential contained (in mM): 140 K‐gluconate, 1 CaCl2, 2 MgCl2, 10 HEPES, 11
EGTA, 3 ATP, and 0.5 GTP; pH 7.2 adjusted with KOH; osmolarity 310 adjusted with K‐
gluconate. A Cs+‐based intracellular solution was used for recording TRPM5 currents
which contained (in mM): 140 Cs‐acetate, 1 CaCl2, 2 MgCl2, 10 HEPES, 11 EGTA, 3 ATP,
and 0.5 GTP; pH 7.2 adjusted with TrisOH; osmolarity 310 adjusted with Cs‐acetate. U‐
73122, an inhibitor of PLC, U‐73343 (inactive analog of U‐73122) and bombesin were
purchased from Sigma (St. Louis, MO). GDP‐β‐S, an inhibitor of G‐proteins was from
Calbiochem (EMD Biosciences, La Jolla, CA).
Electrophysiological recording and analysis. We performed whole‐cell patch
clamp recording to measure membrane potential (current clamp mode) and/or to
record FFA‐induced currents (voltage clamp mode) in STC‐1 cells with an Axopatch‐200B
amplifier (Molecular Devices, Sunnyvale, CA). Patch pipettes were fabricated from
borosilicate glass on a Flaming‐Brown micropipette puller (model P‐97; Sutter
Instrument, Novato, Ca) and subsequently fire polished on a microforge (model MF‐9.
Narishige) to a resistance of 5‐8 MΩ. Commands were delivered and data were recorded
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using pCLAMP software (v. 10, Molecular Devices) interfaced to an Axopatch‐200B
amplifier with a DigiData 1322A analog‐to‐digital board. Data were filtered online at 1
kHz and sampled at 2‐4 kHz.
Membrane potential measurement. The membrane potential (VM) of STC‐1 cells
was recorded continuously before, during and after bitter compound (DB, PTC,
cycloheximide (CYX)) application using the current clamp mode of the amplifier while
holding the cell at its zero current level (i.e. at rest). For recording bitter compounds‐
induced changes in membrane potential, bitter compounds (DB, PTC, CYX) were applied
focally from pipette positioned near cell and controlled by a Picospritzer III (Parker
Hannifin Corp, Cleveland, OH). To determine the ionic dependence of FFA‐induced
changes in membrane potential, VM was recorded in 3 different extracellular solutions
including Tyrode's, sodium free Tyrode's and calcium free Tyrode's.
TRPM5 current recording. Bitter‐induced TRPM5 currents in STC‐1 cells were
recorded using the voltage clamp mode. Typical inward currents were recorded at a
holding potential of ‐100 mV. Bitter compounds were applied focally from a pipette
positioned near the cell and controlled by a PicoSpritzer III (Parker Hannifin Corp)
controlled by the data acquisition and analysis software. Ramp protocols from ‐100 mV
to +100 mV (500 ms duration) were used to generate instantaneous current‐voltage (I‐
V) relationship of bitter‐induced TRPM5 currents in various solutions. All the measured
reversal potentials of DB‐induced currents were corrected for liquid junction potentials.
siRNA construction and transfection. For small interfering RNA experiments, we
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used Silencer® pre‐designed siRNA and Silencer® select pre‐designed siRNA targeted
against TRPM5 (Ambion, Austin TX) according to the manufacturer's directions. As a
negative control, we used the Silencer® control siRNAs kit (Ambion, Austin TX). The
concentration of siRNA used for transfection was 25‐200 nM. STC‐1 cells were reverse
transfected with siRNA complexes using LipofectamineTM 2000 (Invitrogen, Carlsbad CA)
transfection reagent 24‐48 hours prior to performing functional assays or performing
quantitative PCR.
Quantitative RT PCR. RNA was isolated using Tri Reagent® (Molecular Research
Center Inc., Cincinnati, OH) according to manufacturer’s instructions. In real‐time

quantification of mRNA, we used two‐tube RT‐PCR. First‐strand cDNA was synthesized
using an iScript kit from Bio‐Rad (Hercules, CA). The RNA concentration was 50 ng per 20
µl reaction volume. The SmartCycler™ from Cepheid (Sunnyvale, CA) was used to follow
the PCR reaction in real‐time. The HotMaster Taq DNA polymerase kit (5 Prime inc.,
Gaithersburg, MD ) was used for the PCR reaction (final concentration: 1X reaction
buffer, 5 mM Mg2+, 200 µM dNTPs, 60 nM for GAPDH and 1.25 U/µl HotMaster Taq).
Two µl cDNA per reaction was amplified using a 2‐step PCR (6 s denaturation, 60 s
annealing and extension). We used a TaqMan® detection system and primer pairs for
the target sequences were multiplexed with the primer pairs for the housekeeping
gene,

GAPDH

(forward/reverse:

5’

TGCACCACCAACTGCTTAG‐3’

/

5’‐

GGATGCAGGGATGATGTTC‐3’: 487‐496 / 636‐654), for comparison of expression levels
in STC‐1 cells. Primers and probes (5’‐ATCACGCCACAGCTTTCCAGAGGG‐3’; 595‐618) for
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GAPDH were designed using Oligo 6.0 Primer Analysis Software (Molecular Biology
Insights, Inc., Cascade, CO). The GAPDH probe was labeled with ROX as the reporter and
BHQ‐2 as the quencher (Integrated DNA Technologies, Coralville IA). For detection
TRPM5, a commercially available Taqman® Gene Expression Assay (Applied Biosystem,
Foster City CA) was used.
Statistical analysis. The significant effects of all the treatments were determined
by unpaired Student’s t‐test (α=0.05) compared with its appropriate control as
described in the text. Data are presented as mean + SEM, unless otherwise indicated.

Results
Bitter compounds elicit TRP‐like inward currents and membrane depolarization
in STC‐1 cells. In the present study, we have used ratiometric calcium imaging and patch
clamp recording to verify the direct involvement of TRPM5 in the bitter taste
transduction pathway in STC‐1 cells. In whole‐cell voltage clamp experiments (Vh= ‐100
mV), rapid and focal application of DB (10 mM) activated transient receptor potential
(TRP) like inward currents in STC‐1 cells (1730.4 + 132.6 pA; n=12; Fig. 3.1A). Given these
responses, application of DB to STC‐1 cells should elicit a depolarization (receptor
potential). As expected, using current clamp recording, rapid and focal application of DB
(10 mM) caused a large, reversible change in membrane potential in STC‐1 cells (Fig.
3.1B). Moreover, the DB‐induced inward current and depolarization followed a similar
time course consistent with the interpretation that these DB‐induced inward currents
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were capable of depolarizing STC‐1 cells. Previous studies in STC‐1 cells have shown that
DB increased intracellular calcium levels in a dose dependent manner (9). In a similar
vein, Fig. 3.1B shows concentration dependence of DB‐induced inward currents. To
determine the specificity of the bitter‐induced TRP‐like currents, we examined the effect
of two structurally diverse bitter compounds PTC and CYX on STC‐1 cells. PTC (10 mM)
elicited inward current (756.8 + 52.7 pA; n=7; Fig. 3.1C) and depolarized STC‐1 cells (Fig.
3.1D) in a similar fashion to that observed upon application of DB. Application of CYX
(100 µM), however, failed to elicit inward currents or depolarize STC‐1 cells (Fig. 3.1E,
3.1F).
Involvement of G proteins and PLC in DB‐induced inward currents. In order to
examine the involvement of G proteins in the generation of DB‐induced inward current,
GDP‐ß‐S (1 mM), a general inhibitor of G protein activation, was included in the
intracellular solution and DB‐induced inward currents were recorded 2‐3 minutes after
achieving the whole cell configuration. GDP‐ß‐S (138.5 + 53.7 pA; n=7; p<0.001; Fig.
3.2B, 3.2E) caused a significant reduction (>90%) of the magnitude of DB‐induced
inward currents compared to untreated (control) STC‐1 cells (1746.6 + 224.7 pA; n=7;
Fig. 3.2A, 3.2E). To assess the role of PLC in the bitter response in STC‐1 cells, we
measured DB‐induced inward currents while the activity of PLC was blocked by the PLC
antagonist U73122 (3 µM). DB‐induced inward currents were profoundly reduced in the
presence of 3 µM U73122 (301.6 + 93.2 pA; n=5; p<0.001; Fig. 3.2C, 3.2E) when
compared with STC‐1 cells treated with the inactive analog U73373 (3 µM) (1726.6 +
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270.5 pA; n=7; Fig. 3.2D, 3.2E). U73343 treated cells showed no difference in the
magnitude of inward currents in response to DB application compared to untreated STC‐
1 cells (1746.6 + 224.7 pA; n=7; Fig. 3.2A, 3.2E). Previous studies have shown that
TRPM5 plays an essential role in the bitter transduction pathway (36) but bitter‐induced
TRPM5 activity has never been recorded in native cells. In the present study, we
examined involvement of TRPM5 in the generation of DB‐induced inward currents by
using the TRPM5 specific inhibitor, triphenylphosphineoxide (TPPO, 100 µM) (4) to
assess its ability to block the DB‐induced currents in STC‐1 cells. DB‐induced inward
currents were significantly reduced (162.0 + 32.4 pA; n=10; p<0.001; Fig. 3.2F, 3.2G) in
the presence of TPPO (100 µM), suggesting the involvement of TRPM5 in bitter‐induced
inward currents.
DB‐induced inward currents are carried by monovalent cations. To determine
the ion specificity of DB‐induced inward currents in STC‐1 cells, we performed a series of
ion substitution experiments using whole cell patch clamp recording. The DB‐induced
inward currents were virtually abolished in the absence of extracellular sodium ions
(28.6 + 11.7 pA; n=6; p<0.001; Fig. 3.3A, 3.3B) but were unaffected by removal of
extracellular calcium ions (1831.6 + 263.7 pA; n=6; p=0.705; Fig. 3.3A, 3.3B). Similarly,
bitter‐induced depolarization of STC‐1 cells was significantly reduced by removal of
extracellular sodium ions (13.4 + 7.8 mV, n=5) compared to control (62.4 + 4.4 mV, n=4).
To investigate the permeability properties of DB‐induced currents, the reversal
potential (Erev) of the DB‐induced current was measured in a variety of solutions that
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differed in total monovalent cation concentration. Under standard experimental
conditions with equal monovalent cation concentrations on both sides of the membrane
(see Methods), examination of the current‐voltage relationship of DB‐induced currents
revealed a reversal potential of ≈ 0 mV (Fig. 3.3C). This reversal potential is consistent
with activation of a non‐selective monovalent cation permeation pathway, where the
inward current is carried by sodium ions and the outward current is carried by cesium
ions. Assuming the DB‐induced current is carried primarily by monovalent cations, then
the reversal potential for the DB‐induced current should be dependent upon
extracellular sodium ions. As expected, changes in reversal potential of DB‐induced
currents under varying extracellular sodium concentration were closely predicted by
Goldman‐Hodgkin‐Katz (GHK) equation for a monovalent cation selective conductance
(Fig. 3.3C, 3.3D), assuming the permeabilities of potassium, cesium and sodium ions are
equal (27). Experiments in which there was partial removal of intracellular cesium ions
also shifted the reversal potential for the DB‐induced currents in a manner consistent
with the activation of a monvalent cation‐selective pathway (data not shown).
TRPM5 mediates DB and PTC induced currents in STC‐1 cells. Based on our
results showing that DB‐induced currents are permeable to monovalent cations coupled
with the data showing that TPPO inhibited this current, TRPM5 seemed a likely
candidate for carrying these DB‐induced currents. To determine if the currents we were
recording were carried through TRPM5 more directly, we used RNA interference (small‐
interfering RNA; siRNA) to reduce expression of TRPM5 in STC‐1 cells. We transfected
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STC‐1 cells either with siRNA specific to TRPM5 (siTRPM5) or with nonsense sequence
(control, siNEG) and recorded inward currents in response to 10 mM DB and 10 mM
PTC. siTRPM5 treated STC‐1 cells (474.9 + 127.2 pA; n=11; p<0.001; Fig. 3.4B, 3.4E)
showed diminished inward currents in response to DB (10 mM) compared to siNEG
treated STC‐1 cells (1917 + 114.17 pA; n=6; Fig. 3.4A, 3.4E). siNEG treated STC‐1 cells
showed no difference in DB‐induced inward currents compared to untransfected STC‐1
cells. Similar effects were seen with PTC. PTC (10 mM) induced inward currents were
significantly reduced in siTRPM5 treated STC‐1 cells (155.3 + 60.8 pA; n=7; p<0.001; Fig.
3.4D, 3.4E) compared to siNEG treated STC‐1 cells (871 + 92.1 pA; n=5; Fig. 3.4C, 3.4E).
siNEG treated STC‐1 cells showed no difference in the magnitude of PTC‐induced inward
currents compared to untransfected STC‐1 cells.
TRPM5 mediates DB and PTC induced calcium signaling in STC‐1 cells. Previous
studies have shown that DB increases the intracellular calcium concentration in STC‐1
cells by calcium influx through L‐type voltage‐gated calcium channels (9). In STC‐1 cells,
the DB‐induced rise in intracellular calcium concentration has been shown to be
required for CCK release (9). Here, we investigated the direct involvement of TRPM5 in
bitter initiated calcium signaling in STC‐1 cells by using small interfering RNA (siRNA)
specific to TRPM5. Bath application of DB (10 mM) and PTC (10 mM) elicited robust and
reversible increase in intracellular calcium concentration. In STC‐1 cells, resting calcium
levels were between 100‐150 nM and bitter stimuli typically increased the intracellular
calcium concentration several hundred nM. This DB‐induced rise in intracellular calcium
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concentration was significantly reduced in siTRPM5 treated STC‐1 cells (95.0 + 12.1 nM;
n=163; p<0.001; Fig. 3.5B, 3.5E) when compared to siNEG treated STC‐1 cells (321.4 +
20.7 nM; n=83; Fig. 3.5A, 3.5E). The bitter‐induced intracellular calcium response was
similar in both siNEG treated STC‐1 cells and untransfected STC‐1 cells (335.0 + 25.9 nM;
n=87). Similar effects were seen with PTC (10 mM). PTC‐induced rise in intracellular
calcium concentration was profoundly reduced in siTRPM5 treated STC‐1 cells (126.9 +
15.2 nM; n=69; p<0.001; Fig. 3.5D, 3.5E) when compared to siNEG treated STC‐1 cells
(305.2 + 36.5 nM; n=81; Fig. 3.5C, 3.5E). In all STC‐1 cells examined (untransfected,
siNEG treated, siTRPM5 treated), the bombesin (2 µM) induced rise in intracellular
calcium concentration was unaffected (Fig. 3.5A‐D).

Discussion
TRPM5, an ion channel that plays a role in sensory transduction, has been
implicated in bitter, sweet and umami taste perception (26, 36). Numerous studies have
shown that native TRPM5 channels as well those expressed heterologously are activated
directly by calcium ions and display monovalent cation selectivity (15, 21, 27). Despite
the fact that TRPM5 has been identified as a key signaling element in bitter taste,
activation of TRPM5 currents in response to bitter tastants has not been observed in
intact, native cells. Moreover, at cellular level, evidence supporting the involvement of
TRPM5 in bitter transduction has never been shown directly in native cells (i.e. non‐
heterologous expression systems). In present study, we have attempted to record and
characterize bitter‐activated TRPM5 currents in an enteroendocrine cell line, STC‐1.
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STC‐1 cells express various bitter‐activated T2Rs, including receptors for DB, PTC and
CYX (35). Their utility as a model cell line is also evident by the fact that STC‐1 cells
express most of the signaling components identified in Type II taste receptor cells
including alpha gustducin, PLC‐β2 and TRPM5 (9, 30, 34). Moreover, in STC‐1 cells, DB
and PTC have been shown to induce marked increases in intracellular calcium levels in
concentration dependent manner (9). Thus, STC‐1 cells, which have been called the
“taste cells of gut” (12, 28), provide an excellent model system to study and understand
taste transduction pathways for bitter compounds.
In the present study, we provided evidence that two structurally unrelated bitter
compounds DB (5, 7.5, and 10 mM) and PTC (10 mM) induced rapid inward currents in
STC‐1 cells. Transfection of TRPM5 specific siRNA and application of TRPM5 specific
blocker TPPO in to STC‐1 cells showed that DB and PTC induced inward currents are
mediated by TRPM5 channels. This is the first evidence of recording stimulus‐induced
TRPM5 currents in native cells. The inability of siRNA TRPM5 constructs to completely
block bitter‐induced responses could be due to the inability to completely inhibit TRPM5
expression or the activation of additional downstream ion channels. In taste receptor
cells, TRPM5 appears to be involved in final step of the signaling pathway that leads to
membrane depolarization (i.e. the development of a receptor potential). In STC‐1 cells,
we observed that application of bitter compounds DB and PTC elicited depolarization
with time courses similar to that observed in DB‐ and PTC‐induced TRPM5 inward
currents. Inability of CYX (100 µM) to elicit TRPM5 currents, membrane depolarization
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and a rise in intracellular calcium is consistent with an earlier report (35), which shows
that STC‐1 cells express very low mRNA levels of mT2R5, the receptor for CYX.
In taste receptor cells, TRPM5 channels have been hypothesized to function
downstream of T2R (bitter responsive GPCRs) activation. The pathway for bitter
transduction has been shown to involve T2R‐mediated activation of PLC and the
generation of IP3 and DAG, a rise in intracellular calcium concentration and activation of
TRPM5. Support for this model comes from a number of sources: 1) Bitter tastants elicit
marked increases in intracellular calcium concentration (2, 5, 25, 32). 2) PLCβ2, which
generates IP3 by cleavage of PIP2, is required for bitter taste perception (11, 36). 3)
Bitter tastants elicit a rapid rise in IP3 levels (32). 4) Native TRPM5 ion channels,
apparently activated by calcium ions (downstream of IP3 production) (15, 21, 27, 37),
are essential for detection of physiological concentrations of bitter compounds (10, 36).
Despite the overwhelming support for this model, to our knowledge, prior to the data
presented here, there is no direct evidence suggesting that TRPM5 ion channels are
activated downstream of bitter stimulated G protein‐PLC pathway. In the present paper,
we clearly show that bitter‐activated TRPM5 channels function downstream of the G
protein‐PLC signaling pathway.
In addition to providing data on the functional activation of TRPM5 channels by
bitter compounds, we investigated the permeability properties of bitter activated
TRPM5 ion channels in STC‐1 cells. Previous reports using heterologous expression of
TRPM5 have shown that these calcium‐activated channels are nonselectively permeable

93
to monovalent cations and relatively impermeable to divalent cations (15, 21, 27, 37).
Our data from native cells are consistent with these findings. We have shown here that
DB‐induced inward currents are abolished in the absence of extracellular sodium ions
and unchanged in absence of extracellular calcium ions, suggesting that the inward (at
‐100 mV) bitter‐induced TRPM5

currents are mainly carried by sodium ions.

Accordingly, we showed that DB‐and PTC‐induced depolarization is significantly blocked
upon removal of extracellular sodium ions, consistent with the interpretation that DB‐
induced depolarization is mediated by TRPM5 channels. Further, we examined the
current‐voltage (I‐V) relationship of DB‐induced TRPM5 currents under standard
conditions (sodium based extracellular; cesium based intracellular; See Methods) and
found it to be near 0 mV. Removal of extracellular calcium ions did not shift the reversal
potential nor affect the magnitude of DB‐induced TRPM5 currents (data not shown),
suggesting that DB‐induced TRPM5 currents are not dependent on extracellular calcium
ions. Changes in either extracellular sodium concentration or extracellular cesium
concentration, on the other hand, led to changes in reversal potential of DB induced
currents that were closely predicted by Goldman‐Hodgkin‐Katz (GHK) equation for a
monovalent cation selective conductance (27). Taken together, we clearly demonstrate
that DB (and PTC) activates TRPM5 channels in STC‐1 cells that are permeable to
monovalent cations in a nonselective manner and largely impermeable to divalent
cations.
Previous reports have suggested that the bitter‐induced rise in intracellular
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calcium concentration in STC‐1 cells is dependent upon activation of L‐type voltage
gated calcium channels (9). In STC‐1 cells, the DB‐induced rise in intracellular calcium
concentration has been shown to be necessary for CCK release (9). Since we have shown
that bitter stimuli activate cation influx through TRPM5 and that TRPM5 is linked with
depolarization (i.e. the receptor potential), we provided additional evidence linking
TRPM5 activity and calcium influx in STC‐1 cells in this study. RNA interference assays
(specific to TRPM5) clearly suggest the involvement of TRPM5 channels in bitter
initiated calcium influx in STC‐1 cells.
Taken together, we have been able to provide mechanistic support at the
cellular level describing the details of bitter transduction from receptor activation to
calcium influx within STC‐1 cells. In particular, these data provide the first direct
empirical support for the role of TRPM5 in bitter signaling pathways in a chemosensory
cell line. Thus, our data and that of others supports a pathway (Fig. 3.6) whereby bitter
stimuli, like PTC and DB, activate specific T2Rs leading to the activation of PLC and the
generation of IP3 and DAG. IP3‐mediated calcium release (or potentially another
messenger) activates TRPM5. Monovalent cation influx through TRPM5 depolarizes the
STC‐1 cell, opening voltage‐gated calcium channels and allowing the calcium influx
required for release of hormones like CCK from these enteroendocrine cells.
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Figure 3.1: DB and PTC, but not CYX, elicit inward currents and depolarization in STC‐1
cells. (A) Voltage clamp recording showing the activation of inward currents in response
to rapid and focal application (10 sec) of 10 mM DB (Vm = ‐100 mV). (B) Current clamp
recording showing depolarization in response to 10 mM DB. (C) Similar to DB, focal
application of 10 mM PTC elicits inward currents in STC‐1 cells (Vm = ‐100 mV) and leads
to membrane depolarization (D). (E) Voltage clamp recording demonstrates rapid and
focal application (10 sec) of 100 μM CYX failed to activate inward currents (Vm = ‐100
mV). (F) 100 μM CYX failed to initiate membrane depolarization in current clamp
recording. (G) Denatonium elicits concentration‐dependent changes in maginitude of
inweard currents. Responses are shown as mean + SEM current amplitudes during
applications of 5, 7.5, and 10 mM DB.
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Figure 3.2: Inward currents in response to 10 mM DB are sensitive to inhibitors of G
protein activation, PLC and TRPM5. DB‐induced inward currents (Vm = ‐100 mV) in
control (A), GDP‐β‐S (1 mM) treated (B), U73122 (3 μM) treated (C) and in U73343 (3
μM, the inactive analog of U73122) treated (D) STC‐1 cells. (E) Mean DB‐induced current
amplitudes + SEM in control conditions, GDP‐β‐S treatment, U73122 and U73343
treatments in STC‐1 cells. (F) DB‐induced inward currents (Vm = ‐100 mV) in a single STC‐
1 cell in absence and presence of TPPO (100 μM). G) Mean responses + SEM of 10 mM
DB in control conditions and TPPO (100 μM) treatment.
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Figure 3.3: DB‐induced inward currents are dependent upon [Na+]out but not [Ca2+]out.
DB‐induced inward currents (Vm = ‐100 mV) in a single STC‐1 cell in Tyrode's, sodium
free Tyrode's and calcium free Tyrode's (A). (B) Mean responses (inward currents) + SEM
to 10 mM DB in STC‐1 cells in Tyrode's, sodium free Tyrode's and calcium free Tyrode's.
C) Current‐voltage relationship of DB‐induced currents at 10, 60 and 140 mM [Na+]out.
(D) Comparison between theoretical and measured reversal potentials + SEM of DB‐
induced currents recorded at extracellular sodium concentrations of 10, 60 and 140
mM. Values of reversal potentials have been corrected for liquid junction potentials.
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Figure 3.4: DB and PTC induced currents in STC‐1 cells are mediated by TRPM5 channels.
10 mM DB‐induced inward currents in siNEG treated (A) and in siTRPM5 treated (B) STC‐
1 cells. 10 mM PTC induced inward currents in siNEG treated (C) and in siTRPM5 treated
(D) STC‐1 cells. (E) Mean DB and PTC responses (relative inward current to
untransfected cells) + SEM in siNEG treated and siTRPM5‐treated STC‐1 cells. (F) Relative
expression of TRPM5 mRNA in siTRPM5 transfected compared to siNEG transfected STC‐
1 cells assayed by quantitative real time PCR.
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Figure 3.5: TRPM5 mediates bitter compounds DB and PTC initiated calcium signaling in
STC‐1 cells.10 mM DB and bombesin (2 µM) induced [Ca2+]in rise in siNEG treated (A) and
in siTRPM5 treated (B) STC‐1 cells. 10 mM PTC and bombesin (2 µM) induced [Ca2+]in rise
in siNEG treated (C) and in siTRPM5 treated (D) STC‐1 cells. (E) Mean [Ca2+]in responses +
SEM in response to DB and PTC in siNEG treated and siTRPM5‐treated STC‐1 cells.
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Figure 3.6: A working model showing the bitter transduction in STC‐1 cells. Bitter
compounds bind and activate G protein coupled receptors (T2Rs) linked to the
stimulation of a specific isoform of phospholipase C (PLCβ2) and the generation of two
second messengers, diacylglycerol (DAG) and inositol 1,4,5 trisphosphate (IP3). IP3 binds
to IP3 receptors (IP3R) on the endoplasmic reticulum and releases intracellular calcium.
The release of intracellular calcium activates a monovalent cation channel, TRPM5,
whose activation may further depolarize the cell via monovalent cation influx. This
depolarization opens voltage‐gated calcium channels (VGCC) leading to an intracellular
calcium rise and eventual release of satiety hormones like CCK.
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CHAPTER 4
EFFECTS OF POLY‐(LACTIDE‐CO‐GLYCOLIDE) NANOPARTICLES ON
ELECROPHYSIOLOGICAL PROPERTIES OF THE ENTEROENDOCRINE CELL LINE, STC‐1 †

Abstract
PLGA nanoparticles have been widely used to deliver pharmacological
compounds and genes to a variety of cell types. Despite the fact that many of these cells
types depend critically on ion channel activity to function normally, there have been no
studies of the effect of nanoparticle materials on normal ion channel activity. To this
end, we have investigated the effect of nanoparticles on cholecystokinin (CCK) releasing
enteroendocrine cell (EEC) line STC‐1, which play a central role in regulating food intake.
It has been shown that regulation of CCK release from STC‐1 cells in response to fat,
carbohydrate and protein depends on the normal electrogenic properties of the cell,
including a strict dependence upon the activity of voltage‐gated calcium and potassium
channels. Because of the importance of voltage‐gated ion channels in the normal
physiological responses of STC‐1 cells, we have done electrophysiological (patch clamp)
experiments to assess the effects of PLGA nanoparticles on the voltage‐gated calcium
and potassium channels. Whole‐cell patch clamp recording on STC‐1 cells containing 100
nm nanoparticles showed no macroscopic differences in calcium and potassium channel
activity. Moreover, additional experiments in which we have determined the activation,
inactivation, use‐dependent inactivation of these voltage‐gated ion channels have failed
†
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to demonstrate a significant effect of nanoparticles on these basic biophysical
properties. Lastly, we examined the effects of PLGA nanoparticles on stimulus induced
rise in intracellular calcium concentration in STC‐1 cells, which is necessary for release of
CCK. Our data support the use of PLGA nanoparticles as an attractive option for
delivering pharmaceuticals/genes to cells of the digestive system that might eventually
prove useful for reducing appetite/food intake.

Introduction
The gastrointestinal hormone cholecystokinin (CCK) regulates wide variety of
physiological functions (11, 12, 23, 32). As is typical of many gastrointestinal hormones,
CCK is produced by enteroendocrine cells (EECs) of intestinal mucosa which are
concentrated in duodenum and proximal jejunum (18). Release of CCK from EECs, which
functions as short‐term satiety cue, is considered one of the most important signals to
the control of food intake (e.g. satiety) during the course of a meal (34, 40). CCK release
is stimulated both by specific nutrients, such as fats, fatty acids, carbohydrates and
protein, as well as by a number of additional neuromodulators that have been shown to
contribute to the control of food intake (for review on CCK, (18)). It is believed that an
increase in secretion of endogenous CCK from EECs would help limit the meal size and
eventually food intake (19).

However, as is the case for many receptor‐mediated

pathways in the body, specific receptors are expressed in a variety of physiological
targets. It is important, therefore, to investigate the use of carriers such as nanoparticles
for specific and controlled delivery of therapeutic agents that enhance CCK secretion
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from EECs.
Nanoparticles, submicron sized colloidal particles with encapsulated, adsorbed
or conjugated compounds of interest, have been widely used in various drug delivery
applications (22, 25).

Recently, the use of biodegradable synthetic polymers to

formulate nanoparticles for targeted and sustained delivery of pharmacological agents
has been extensively investigated. Of all the synthetic biodegradable polymers, poly
(D,L‐lactide‐co‐glycolide) (PLGA), has attracted the most attention in research for its use
in various drug delivery applications because of its unique properties (15, 17). PLGA has
been studied extensively for its biocompatibility and is approved by the FDA for human
use (1, 2, 13). Different proteins, peptides, blockers, genes, small interfering RNA
(siRNAs), vaccines, antigens, human growth factors have been successfully incorporated
into PLGA based nano/microparticles (4, 6, 20, 31). Moreover, following their uptake
inside the cells, PLGA nanoparticles have been shown to escape degradative endo‐
lysosomal compartments to the cytoplasmic compartment, thus increasing therapeutic
efficacy (26). Because of 1) efficient intracellular uptake; 2) rapid escape from
degradative endo‐lysosomal compartments to the cytoplasmic compartment; 3) longer
intracellular retention; and 4) ability to maintain therapeutically relevant doses of
pharmaceutical compounds in the cytoplasm over prolonged periods, PLGA
nanoparticles have been in the common choice for intracellular drug delivery of
compounds such as peptides, proteins and DNA (24‐28).
The use of PLGA nanoparticles to increase endogenous CCK secretion from
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enteroendocrine cells by delivering pharmacological agents and/or gene constructs
could be a valuable strategy to decrease food intake. In present study, we have begun to
explore this possibility. First, we have characterized intracellular uptake of PLGA
nanoparticles in an enteroendocrine cell line, STC‐1. STC‐1 cells have been widely used
to study regulation of gastrointestinal (GI) hormone (such as CCK, GLP‐1) release in
response to various stimuli including nutrients (fatty acids, protein, carbohydrates),
tastants (bitter) and hormones (5, 14). Voltage‐gated potassium channels and calcium
channels play a central role in satiety hormone release in EECs (21, 33, 35). To ensure
that nanoparticles themselves do not interfere with the normal electrophysiological
processes related to CCK release in STC‐1 cells, we have performed experiments to
determine effect of PLGA nanoparticles on activation and inactivation kinetics of
voltage‐gated potassium and calcium channels. Lastly, we examined the effects of PLGA
nanoparticles on stimulus induced rise in intracellular calcium concentration in STC‐1
cells, which is necessary for release of CCK. Our data support the use of PLGA
nanoparticles as an attractive option for delivering pharmaceuticals/genes to cells of the
digestive system that might eventually prove useful for reducing appetite/food intake.

Materials and Methods
Materials. Poly (D,L‐lactide‐co‐glycolide) (PLGA, MW 143900, co‐polymer ratio
50:50) was purchased from Birmigham Polymer Inc. (Birmigham, Al). Various tissue
culture items including FBS, DMEM, trypsin were purchased from ThermoFisher
Scientific Inc., (Logan, UT). Linoleic acid and bombesin were purchased from Sigma
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Chemical Co. (St. Louis, MO).
Cell culture. The murine enteroendocrine cell line STC‐1, was a generous gift
from Dr. D. Hanahan (University of California, San Francisco). STC‐1 cells were derived
from an intestinal endocrine tumor developed in double transgenic mouse expressing
the insulin promoter linked to simian virus 40 large T antigen and polyoma virus small T
antigen. STC‐1 cells were cultured using Dulbecco’s modified Eagle’s medium containing
10% (v/v) fetal bovine serum (FBS) in 5% CO2 at 37°C. STC‐1 cells were plated on glass
coverslips 24‐48 hours prior to nanoparticle uptake, calcium imaging and
electrophysiological studies. Cells were grown to about 90% confluency. Upon reaching
90% confluency, cells were either passaged or used for experiments. All STC‐1 cells used
for the experiments were between passages 4‐12.
PLGA nanoparticles fabrication. The PLGA nanoparticles were formulated using
the standard emulsion – solvent evaporation method (7). In brief, a 3% (w/v) PLGA
solution was made by dissolving PLGA in chloroform and to this 100 µl of 6‐coumarin
solution (0.005% in chloroform) was added. The above solution was added dropwise
into a 2.5% (w/v) polyvinyl alcohol (PVA) solution under stirring to form the emulsion.
The emulsion was then sonicated (Misonix Inc., Farmingdale, NY) at 45 W for 3 minutes
in 1 minute cycles. The emulsion was stirred overnight to allow for evaporation of the
solvent and then centrifuged (Beckman Coulter, Inc., Fullerton, CA) at 30,000 rpm for 20
minutes at 15° C. The pellet was washed two times, resuspended in DI water, frozen at
‐800C and lyophilized for 72 hours.

Lyophilized nanoparticles were then used
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immediately or stored at 4°C until use.
Measurement of ζ potential. Nanoparticles were characterized for the particle
size and zeta potential using the ZetaPALS instrument (Brookhaven Instruments
Corporation, Holtsville, NY). The samples were prepared by suspending 1 mg/ml
nanoparticles in DI water and sonicating the sample for 30 seconds at 30 W.
SEM analysis of PLGA nanoparticles. Dry PLGA particles were diluted, sonicated
and placed on coverslips coated with 0.1% poly‐L‐lysine. This preparation was allowed to
dry overnight and sputter coated with gold (IBS/TM200S Ion Beam Sputterer, VCP Group
Inc.). Images of samples were studied using SEM (Hitachi S‐4000).
Nanoparticle uptake studies. Cellular uptake experiments included optimal time,
dosage, and biocompatibility analysis. In order to evaluate cellular uptake of PLGA
nanoparticles, STC‐1 were seeded on a 24 well plate (Falcon®, Becton Dickinson
Labware) at a density of 20,000 cells per well and grown for 2 days. A nanoparticle
stock solution was prepared at a concentration of 1 mg/ml in complete DMEM. The
nanoparticle solution was re‐suspended in a water bath sonicator for 10 minutes. For
the dose studies, the concentration of nanoparticle solution was varied between 0‐500
µg/ml and was prepared from the stock solution. The media was removed from the 24‐
well plate and replaced with the various concentrations of nanoparticle solution. Cells
were incubated with these solutions for one hour in 5% CO2 at 37°C. After one hour of
incubation, cells were washed 3 times with phosphate buffered saline (PBS), and lysed
with 1% Triton®‐X 100 for 1 hour. The temporal study was performed over a period of
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six hours with cells being incubated with nanoparticles at a concentration of 100 μg/ml.
The nanoparticle solution was added to the wells and incubated for 0‐6 hours at 37°C.
At the end of the time study, nanoparticle solutions were removed and the wells were
washed thrice with PBS to remove any remaining nanoparticles. Triton®‐X 100 (1%) was
then added to the wells and incubated for 1 hour at 37°C in order to lyse the cells.
For analysis of concentration‐ and time‐dependent uptake, the collected cell
lysates were analyzed for total cell protein content using the Pierce BCA protein assay
and for the nanoparticle uptake by measuring fluorescent intensities. For the Pierce
BCA protein assay (Fisher Scientific), 25 µl of cell lysate was used. The working reagent
was added to the lysate samples, and incubated at 37°C for 30 minutes after which the
absorbance of the sample was measured by a microplate reader (Infinite M200,Tecan
USA, Inc.) at 562 nm. The total cell protein was determined against a BSA protein
standard curve. To determine the amount of nanoparticles internalized by cells, 200 µl
of cell lysate from each sample was added to a 96 well plate and fluorescent intensity of
the samples was measured at EM 480 nm/EX 510 nm.

Serial dilutions of stock

nanoparticle solution in 1% Triton®‐X 100 were used to obtain a standard curve. The
uptake of the nanoparticle by STC‐1 cells was calculated by normalizing the particle
concentration with the total cell protein of each sample.
Nanoparticle uptake by confocal microscopy. Uptake of nanoparticles was also
visualized using confocal microscopy. STC‐1 cells were seeded on glass coverslips
(Fisherbrand®, Fisher Scientific) at a density of 3x104 cells/cm2 and grown similar to that
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of tissues culture well plates as described earlier. For confocal experiments, cells were
incubated with 100 µg/ml of PLGA nanoparticle solution for 30 minutes to 4 hours, and
then washed with PBS.

Following incubation with PLGA nanoparticles, cells were

incubated with cell membrane dye FM® 4‐64 FX (Texas‐Red® dye, Invitrogen) at 5 µg/ml
in PBS for 5‐10 minutes. Samples were observed using a Leica confocal laser scanning
microscope equipped with a FITC filter (Ex(λ) 478 nm, Em(λ) 515 nm) and TRITC (Ex(λ)
465 nm, Em(λ) 744 nm) with the option of stacking sample sections.
Biocompatibility. To determine the biocompatibility of the PLGA nanoparticles
with STC‐1 cells, a MTS (3‐(4,5‐dimethylthiazol‐2‐yl)‐5‐(3‐carboxymethoxyphenyl)‐2‐(4‐
sulfophenyl)‐2H‐tetrazolium) cytotoxicity assay (Promega Corp.) was performed. The
cells were seeded at a density of 2x104 cells/cm2 and allowed to grow for two days. On
the day of the experiment, cells were incubated for six hours with varying
concentrations (0‐1000 µg/ml) of nanoparticle solutions. The MTS assay was then
performed as per the manufacturer’s instructions.
Electrophysiological recording and analysis. We performed whole‐cell patch
clamp recordings on STC‐1 cells that either had or had not taken up PLGA nanoparticles.
Currents in STC‐1 cells were recorded with an Axopatch‐200B amplifier (Molecular
Devices, Sunnyvale, CA) that was interfaced to a computer running pCLAMP software (v.
10; Molecular Devices) with an A‐to‐D board (Digidata 1322A, Molecular Devices). Patch
pipettes were fabricated from borosilicate glass on a Flaming‐Brown micropipette puller
(model P‐97; Sutter Instrument, Novato, CA) and subsequently fire polished on a
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microforge (model MF‐9, Narishige) to a resistance of 5‐8 MΩ. Data were filtered online
at 1 kHz and sampled at 2‐4 kHz. Patch pipettes were filled with a standard intracellular
solution containing (in mM): 140 KCl, 1 CaCl2, 2 MgCl2, 10 HEPES, 11 EGTA, 3 ATP, and
0.5 GTP; pH 7.2 adjusted with KOH; osmolarity was 310 mOsm. For recording potassium
currents, standard extracellular saline (Tyrode's) was used containing (in mM): 140 NaCl,
5 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose, and 10 Na pyruvate; pH 7.40 adjusted with
NaOH; osmolarity was 310 mOsm. For recording calcium currents, a barium Tyrode's
solution containing 103 mM barium chloride, 10 mM TEA bromide, 1 mM CaCl2, 1 mM
MgCl2, 10 mM HEPES, 10 mM glucose, 10 mM Na pyruvate and 0.001 mM TTX was used.
PLGA nanoparticles were also added in the extracellular solution during patch clamp
recording to reduce net exocytosis during the recording session.
Intracellular calcium imaging. STC‐1 cells were loaded with Fura‐2/AM (5 µM;
Molecular Probes, Eugene, OR) for 1 hour in Tyrode's with 10% pluronic acid at 37°C in
the dark. Cells were then rinsed and placed in media for 30 minutes to allow de‐
esterification of acetoxymethyl ester group from Fura‐2. The coverslips were mounted
onto the chamber (RC‐25F, Warner Instruments, Hamden, CT), placed on an inverted
microscope (Nikon, Eclipse TS100, Japan) and perfused continuously with Tyrode's. Cells
were illuminated with a 100‐watt xenon lamp and excitation wavelengths (340/380 nm)
were selected by a monochromator (Bentham FSM150, Intracellular Imaging Inc.,
Cincinnati, OH) at a rate of 20 ratios per minute. Fluorescence was measured by a CCD
camera (PixelFly, Cooke, MI) coupled to a microscope and controlled by software (Incyt
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Im2, Intracellular Imaging). The fluorescence ratio (340/380) was directly converted to
calcium concentrations using a standard curve generated for the imaging system using
Fura‐2 calcium imaging calibration kit (Molecular Probes, Eugene, OR). Working
solutions of fatty acid and bombesin were made in Tyrode's and applied with a bath
perfusion system. PLGA nanoparticles were also added in the extracellular solution to
reduce net exocytosis during the recording session.
Statistical analysis. Significant effect of internalized PLGA nanoparticles on
linoleic acid and/or bombesin induced intracellular calcium rise were determined by
unpaired Student’s t‐test (α=0.05) compared with control. Data are presented as mean
+ SEM, unless otherwise indicated.

Results
Characterization of PLGA nanoparticles. PLGA nanoparticles ranging in size from
60 to 300 nm (mean diameter: 119 + 55 nm; Fig. 4.1A) were obtained by making oil‐
water emulsions with specific formulation parameters and energy source inputs. To
confirm these formulations were in the appropriate size range, we did scanning electron
microscope (SEM) image analysis of PLGA nanoparticles. As shown in Figure 4.1B, similar
to results from the particle size analysis, PLGA nanoparticles ranged in size was ranging
from 60 to several hundred nm with exception of larger particles in very few numbers
compared to smaller nanoparticles. The surface of PLGA nanoparticles was found to be
smooth and nonporous from SEM image analysis (Fig. 4.1B). The ζ potential (measure of
surface charge) of PLGA nanoparticles was ‐16.99 mV.
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Uptake of PLGA nanoparticles by STC‐1 cells. For intracellular uptake studies,
the fluorescent dye 6‐coumarin was incorporated in PLGA nanoparticles during their
formulation. We further examined the intracellular uptake of PLGA nanoparticles in
enteroendocrine cell line, STC‐1 cells by employing fluorometric quantitative
measurement as well as confocal microscopy. Incubation of PLGA nanoparticles (100
μg/ml) with STC‐1 cells for various times shows that intracellular uptake of PLGA
nanoparticles in STC‐1 cells is time‐dependent (Fig. 4.2A; n=8 for each time point).
Uptake of PLGA nanoparticles in STC‐1 cells was seen as early as 30 minutes and
increased gradually over time (Fig. 4.2A). Intracellular uptake of PLGA nanoparticles in
STC‐1 cells was also found to be concentration dependent (Fig. 4.2B; n=8 for each
concentration). Figure 4.2B shows that intracellular uptake peaked at 100 μg/ml
concentration and then reached a plateau.
From the confocal microscopy images of PLGA nanoparticles loaded STC‐1 cells
(taken 8‐10 µm below the cell surface), it was evident that elevated fluorescent activity
in STC‐1 was observed at the 2‐hour and 4‐hour time points compared to the
fluorescence observed at 30 minutes (Fig. 4.3A‐C). We examined the possibility that the
fluorescence observed in STC‐1 cells was associated with 6‐coumarin bound with
nanoparticles and not free 6‐coumarin by performing a conventional dye release study
(7). Intracellular fluorescence was insignificant in cells incubated with 6‐coumarin
solution released from nanoparticles when compared to cells incubated with
nanoparticles (Fig. 4.3E‐F). Further, cytotoxicity assay shows that PLGA nanoparticles
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concentrations up to 500 μg/ml did not affect cell viability (Fig. 4.2C; n=8 for each
concentration).
Effects of PLGA nanoparticles on ion channels of STC‐1 cells. It has been shown
that regulation of CCK release from STC‐1 cells in response to fat, carbohydrate and
protein depends on the normal electrogenic properties of the cell, including a strict
dependence upon the activity of voltage‐gated calcium channels and potassium
channels (21, 33, 35, 37). Because of the importance of voltage‐gated ion channels in
the normal physiological responses of STC‐1 cells, we have performed whole‐cell patch
clamp recording to assess the effects of PLGA nanoparticles on voltage‐gated calcium
and potassium channel activity. In order to examine the effect of PLGA nanoparticles on
the activity of voltage gated calcium and potassium channels, we incubated STC‐1 cells
with 6‐coumarin tagged PLGA nanoparticles (size ≈100 nm, time = 2 hours,
concentration = 100 μg/ml) to allow optimal intracellular uptake. Whole‐cell patch
clamping was performed on cells that showed fluorescence under UV light. Voltage‐
gated calcium and potassium currents were activated in response to application of
series of voltage steps from ‐80 mV to +40 mV. Whole‐cell patch clamp recording on
STC‐1 cells containing 100 nm PLGA nanoparticles showed no macroscopic differences in
calcium and potassium channel activity (Fig. 4.4).
Further, we investigated activation and inactivation properties of voltage gated
calcium and potassium ion channels in presence and absence of PLGA nanoparticles in
STC‐1 cells, as modulation in activation and inactivation properties of these channels can
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lead to profound effects on signaling cascades culminating in to CCK and GLP‐1 release.
Our data demonstrates that PLGA nanoparticles do not alter activation (conductance vs.
voltage) (Figure 4.5A), use dependent inactivation (Figure 4.5B) and voltage dependent
inactivation (Figure 4.5C) properties of voltage‐gated potassium ion channels. PLGA
nanoparticles also did not cause any alteration in activation (data not shown) and
voltage dependent inactivation (Figure 4.5D) properties of voltage‐gated calcium
channels.
In STC‐1 cells, various stimuli induce a rise in intracellular calcium concentration
either by calcium influx through voltage gated calcium channels or by calcium release
from intracellular stores (5, 37). Elevation of intracellular calcium concentrations by
either mechanism is thought to be necessary and sufficient for stimuli induced CCK and
GLP‐1 release in STC‐1 cells. Next, we examined the effects on PLGA nanoparticles on
the stimulus‐induced intracellular calcium rise in STC‐1 cells using the ratiometric dye
Fura‐2‐AM imaged in combination with a high speed ratiometric calcium imaging system
(InCyt2‐IM; Intracellular Imaging, Inc. Cincinnati, OH). As shown in Figure 4.6A, linoleic
acid (30 µM) elicits a robust and reversible increase in intracellular calcium
concentration in STC‐1 cells. On an average 30 µM linoleic acid elicited 349.0 ± 10.7 nM
increase in intracellular calcium in STC‐1 cells (n=114; Figure 4.6C). PLGA nanoparticles
did not change linoleic acid (30 µM) induced intracellular calcium rise in STC‐1 cells
(320.0 ± 34.0 nM, n= 47; Figure 4.6B‐C). Moreover, the bombesin (2 µM) induced
calcium response was not altered in PLGA nanoparticle loaded STC‐1 cells (349.2 + 13.1
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nM, Figure 4.6E, 4.6F) when compared to control STC‐1 cells (343.1 + 18.2 nM, Fig. 4.6D,
4.6F). Lastly, we determined the effects of PLGA nanoparticles on resting calcium levels
in STC‐1 cells and no significant difference was observed (control STC‐1 cells: 134.6 ± 8.1
nM, n=114; PLGA nanoparticles loaded STC‐1 cells: 139.0 ± 5.7 nM, n=47).

Discussion
The recent development of nanoparticle technology, wherein small (~100 nm)
particles are delivered to specific tissues and are taken up inside cells to deliver drugs
and genetic material, is ideally suited to overcome the problem of non‐specific drug
targeting. Recently, biodegradable polymers such as PLGA have been extensively used
and studied for nanoparticle‐mediated drug delivery applications by various groups (3,
6‐8, 16, 17, 38). Different proteins, peptides, blockers, genes, small interfering RNA
(siRNAs), vaccines, antigens, human growth factors are successfully incorporated in to
PLGA based nano/microparticles (4, 6, 20, 31).
Nanoparticle‐mediated targeted drug/gene delivery to EECs to potentially
increase CCK secretion and ultimately reduce food intake, would be of great therapeutic
importance. In the present report, we fabricated PLGA nanoparticles of about 100 nm in
diameter using oil‐water emulsion solvent evaporation technique (7). Previous findings
demonstrated that 100 nm PLGA nanoparticles have advantages over larger diameter
nanoparticles in degradation (10), drug release profiles, tissue penetration (8, 39) and
intracellular nanoparticle uptake (9, 29). Results from the particle size analyzer and
scanning electron microscopy reveals the average size of PLGA nanoparticles is
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approximately 100 nm. Further, we determined ζ potential of nanoparticles (measure of
surface charge) as it can affect particle stability, intracellular uptake, mucoadhesion as
well as intracellular trafficking of particle (2, 26). The ζ potential measurement of PLGA
nanoparticles is ‐16.99 mV, which may ensure the reduction in aggregation of
nanoparticles. One of the most sticking characteristics of PLGA polymers is that it shows
transition in its surface charge (ζ potential) from anionic (at pH=7) to cationic in acidic
environment (at pH=4). By using the above strategy, upon intracellular uptake, PLGA
nanoparticles have been shown to escape (rapidly, within 10 minutes) from acidic
endosomes/lysosomes to cytoplasm, thus increasing the efficacy of delivering payloads
inside the cells (26).
Next, we characterized intracellular uptake of PLGA nanoparticles in STC‐1 cells.
Our results show that PLGA nanoparticle internalization in STC‐1 cells is both time and
concentration dependent as observed before with different cell types (7). Confocal
microscopy results clearly demonstrate that PLGA nanoparticles are internalized in the
STC‐1 cells and not just bound to the cell surface. Moreover, from dye release study, it is
clear that fluorescence observed in STC‐1 cells is due to 6‐coumarin dye associated with
PLGA nanoparticles and not because of free released 6‐coumarin dye.
Toxicity is a serious concern in drug delivery applications and various cationic‐
polymers and lipid based transfection reagents have been implicated in causing
cytotoxicity at higher concentrations (30). Biocompatibility/cytotoxicity assays showed
that STC‐1 cell viability is not affected by PLGA nanoparticles in concentration range of
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50‐500 μg/ml. However, it does not necessarily mean that PLGA nanoparticles are not
interfering with normal physiological processes in the cells. Despite the fact that cells
types depend critically on ion channel activity to function normally, there have been no
studies that focus on examining the effect of nanoparticle materials on normal ion
channel activity. In STC‐1 cells, it has been shown that regulation of CCK in response to
fat, carbohydrate and protein depends on the normal electrogenic properties of the cell,
including a strict dependence upon the activity of voltage‐gated calcium and potassium
channels (21, 33, 35, 37). Modulation of activation or inactivation properties of voltage‐
gated potassium and calcium channels could lead to hyper‐ or hypo‐excitability of cells
which both could be potentially dangerous. Thus, we examined the effects of
internalized PLGA nanoparticles on voltage‐gated calcium and potassium channels.
Our results clearly showed that PLGA nanoparticles have no significant effects on
activation and inactivation properties of voltage‐gated calcium and potassium channels.
While we have focused our attention on these two channel classes and found no
differences, it remains possible that other ion channel or receptor types could be
affected by the internalization of PLGA nanoparticles. While we consider this unlikely
given our data, we nonetheless extended our studies to examine the effects of
internalized PLGA nanoparticles on signaling pathways, one a receptor‐mediated
pathway involving fatty acid‐sensitive G protein coupled receptors, and another
involving intracellular release of calcium by the hormone bombesin. Each of these
pathways leads to elevation of intracellular calcium concentrations. Since elevation of
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calcium concentrations inside the cells is a highly regulated process and important to
multiple signaling phenomena with myriads of physiological effects, we felt this was
another way to validate the use of this approach. In STC‐1 cells, prototypical PUFA
stimulus linoleic acid, which activates the G protein coupled receptor GPR120 (14),
induces a rise in intracellular calcium concentration by activating downstream calcium
influx through voltage gated calcium channels (unpublished data, (37)). Bombesin,
which primarily acts to stimulate gastrin release from G cells of the stomach, induces a
rise in intracellular calcium concentration by calcium release from intracellular stores (5,
36). Elevation of intracellular calcium concentration by either mechanism is thought to
be necessary and sufficient for stimuli induced CCK and GLP‐1 release in STC‐1 cells.
Calcium mobilization in response to linoleic acid was unaffected in presence and
absence of internalized PLGA nanoparticles, suggesting that nanoparticles do not
interfere with linoleic acid initiated signaling in STC‐1 cells. Moreover, PLGA
nanoparticles did not affect calcium signaling initiated by bombesin.
We have shown that PLGA nanoparticles are taken up into an enteroendocrine
cell line within appropriate concentration and temporal ranges for their potential utility
in the control of food intake. Moreover, the uptake of these particles does not appear to
interfere with any signaling pathway examined, including ion channel and receptor‐
mediated pathways. Taken together, our data argue to the validity of using a PLGA
nanoparticle‐mediated approach to deliver pharmaceuticals or genes to the digestive
system, particularly those cells that may be important for the eventual control of food
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intake.
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Figure 4.1: Size distribution and SEM image of PLGA nanoparticles. (A) size distribution
of PLGA nanoparticles by estimated by nanoparticle size analyzer (LS230, Beckman
Coulter). (B) SEM image of PLGA nanoparticles (~100 nm) Scale bar, 450 nm.
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Figure 4.2: Intracellular uptake of PLGA nanoparticles in STC‐1 cells is both time and
concentration dependent. (A) Time‐dependent uptake of PLGA nanoparticles (~100 nm;
dose=100μg/ml) in STC‐1 cells. (B) Concentration‐dependent uptake of PLGA
nanoparticles (~100 nm; incubation time=1 h) in STC‐1 cells. (C) The effect of
nanoparticle concentration on STC‐1 cell viability. Each data point represents mean +
SEM (n=8).
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Figure 4.3: Fluorescent confocal microscopic images of STC‐1 cells loaded with
PLGA nanoparticles (~100 nm). A‐C represent fluorescent confocal microscopic images
of STC‐1 cells loaded with PLGA nanoparticles(~100 nm) at incubation times of 0.5, 4, 6
hours respectively. (D) membrane integrity of STC‐1 cells remains intact upon uptake of
PLGA nanoparticles (~100 nm; incubation time = 2h). Membrane was labeled with the
membrane‐selective dye, FM4‐64, in red. (E) Represent fluorescent confocal
microscopic image of STC‐1 cells loaded with PLGA nanoparticles (~100 nm; incubation
time = 1 h). (F) Represent fluorescent confocal microscopic image of STC‐1 cells loaded
with 6‐coumarin solution released from nanoparticles in vitro (2 hours; incubation time
= 1 h).
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Figure 4.4: Typical potassium (top) and calcium (bottom) currents in absence (A) and
presence (B) of PLGA nanoparticles in STC‐1 cells. Voltage steps from ‐80 mV to +40
mVwere used to elicit the currents in these examples. There were no macroscopic
differences observed in either calcium or potassium currents in either condition.
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Figure 4.5: The PLGA nanoparticles do not alter activation and Inactivation
characteristics of voltage gated potassium and calcium channels. (A) Normalized
conductance (in response to test pulses) is plotted versus test voltages (‐80 to +40) in
the presence (‐) and absence (‐) of nanoparticles. There are no significant differences
between the two conditions. (B) Use dependent inactivation curves for potassium
currents in STC‐1 cells. The presence of nanoparticles had no effect on use‐dependent
inactivation. Inset, voltage protocols used. (C) Voltage‐dependent inactivation curves for
potassium currents in STC‐1 cells. There is no significant difference in inactivation
characteristics between the control and nanoparticle conditions. Inset, voltage protocols
used. (D) Voltage‐dependent inactivation curves of calcium channels in STC‐1 cells with
and without nanoparticles. Inactivation characteristics of calcium channels were not
significantly affected by nanoparticle uptake. Inset, voltage protocols used. Data are
shown ± SEM.
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Figure 4.6: The PLGA nanoparticles do not interfere with linoleic acid and
Bombesin induced calcium signaling in STC‐1 cells. The rise in intracellular calcium
concentration recorded upon application of 30 μM linoleic acid in absence (A) and
presence (B) of PLGA nanoparticles taken up by STC‐1 cells. (C) Mean amplitude (nM) +
SEM of 30 μM linoleic acid responses in absence and presence of PLGA nanoparticles.
Intracellular calcium concentration recorded during application of 2 μM bombesin in
absence (D) and presence (E) of PLGA nanoparticles. (F) Mean amplitude (nM) + SEM of
2 μM bombesin responses in the absence and presence of PLGA nanoparticles. There
were no significant differences in either response due to nanoparticle uptake.
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CHAPTER 5
SUMMARY AND FUTURE DIRECTIONS

One of the primary goals of my dissertation work was to explore the signal
transduction pathway involved in the free fatty acid initiated intracellular calcium rise,
which is necessary and sufficient for secretion of satiety peptides such as
cholecystokinin (CCK). Using quantitative RT‐PCR (Figure 5.1), I have shown that STC‐1
cells express a variety of fatty acid activated receptors including GPR40, GPR120, GPR43
and CD36. The identification of these receptors was critical for meeting our initial
objective of trying to identify putative targets involved in the fat‐induced pathway
leading to CCK release. The identification of these receptors, however, also necessitated
a change on the overall direction of the research program and my specific interests
since little was known about the fatty acid signaling pathway in the gut. As a result,
much of the research undertaken in this dissertation was focused on the elucidation of
the fatty acid signaling pathways in the enteroendocrine cell line, STC‐1.
To this end, much of the research I undertook was a cell‐based approach (patch
clamp recording and functional calcium imaging) to study fatty acid signaling in STC‐1
cells. I have gathered significant data in support of our working model for fatty acid
transduction (Fig. 5.4). Using ratiometric calcium imaging and RNA interference assays, I
have shown that linoleic acid elicits a rise in intracellular calcium concentration by
activating GPR120, arguing to the importance of GPR120 and not GPR40, in the
transduction of linoleic acid. Removal of extracellular calcium ions (Fig. 2.1B, D) and/or
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use of nicardipine (blocker of L‐type voltage‐gated calcium channels) (Fig. 5.2)
significantly reduced linoleic acid induced rise in intracellular calcium concentration,
suggesting that linoleic acid induced rise in intracellular calcium levels are largely
mediated by calcium influx through L‐type voltage gated calcium channels. From whole‐
cell current clamp experiments, I found that linoleic acid depolarizes STC‐1 cells (Fig.
2.1E). Interestingly, despite almost a decade of experiments exploring the effects of
fatty acids on chemosensory cells, these are the first data showing that fatty acids, like
linoleic acid, could induce membrane depolarization.
Considerable time and effort was spent during the course of my research to try
and determine the specifics of the fatty acid transduction pathway following receptor
activation. Using pharmacological blockers to block the activity of G proteins and PLC, I
showed that linoleic acid induced depolarization is downstream of activation GPCR
signaling (Fig. 2.2A‐E). Further I provided data that extracellular sodium ions, but not
extracellular calcium ions, are required for linoleic acid induced depolarization (Fig. 2.1F‐
H). These results may indicate that sodium entry is necessary for depolarization in STC‐1
cells upon linoleic acid application and that calcium influx is downstream of sodium
entry (depolarization). This latter observation is also supported by the finding that
extracellular sodium ions are required for linoleic acid induced calcium rise in STC‐1
cells. Further to determine the link between GPR120 and development of the receptor
potential (depolarization) in STC‐1 cells, I recorded and characterize linoleic acid induced
inward currents in STC‐1 cells. From RNA interference assays and using TPPO (a specific
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blocker of TRPM5), I showed that linoleic acid induced inward currents are mediated by
TRPM5 ion channels expressed in STC‐1 cells (Fig. 3.4A‐E). I have also established that
linoleic acid induced activation of TRPM5 channels is downstream of GPR120 (Fig. 3.5A‐
C). To our knowledge, these are the first direct data showing that TRPM5 functions
downstream of GPCR signaling. Finally, I showed that TRPM5 plays a very important role
in linoleic acid induced rise in intracellular calcium concentration. Further, involvement
of TRPM5 in linoleic acid induced CCK release is yet to be determined. Comparing the
CCK and GLP‐1 levels in plasma in response to intraduodenal fatty acid infusion in wild
type and TRPM5 null mice would validate the role of TRPM5 in fatty acids signaling in
enteroendocrine cells.

It is important to recognize that, despite my progress in

elucidating this transduction pathway, this research was focused almost entirely upon
the PUFA, linoleic acid. It is feasible, if not likely, that other fatty acids may utilize other
receptors and other pathways to activate these cells. Future research focused upon the
applicability of these pathways to other fatty acids is warranted.

How Do Delayed Rectifying Potassium Channels Fit In?
The role of delayed rectifying potassium (DRK) channels as putative fat receptors
has been shown in the peripheral gustatory system, where inhibition of DRK channels in
mammalian taste receptor cells (TRCs) has been proposed as a mechanism underlying
the taste of fat (4). Prior to the identification of the fatty acid‐activated GPCRs, these
channels were the primary focus of this research plan. However, early during the course
of this research it became evident that the DRK channels were probably not the primary
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receptors for fatty acids in chemosensory cells. As noted in our working model for fatty
acid transduction, delayed rectifying potassium still contribute to fatty acid signaling,
but may play a role to enhance the depolarization generated by GPCR activation
upstream. The studies from our laboratory in obesity‐prone and –resistant rats suggest
that the ratio of fatty acid‐sensitive (fa‐s) to fatty acid‐insensitive (fa‐i) delayed rectifying
K+ channels contributes to differences in dietary fat preference (5). Using heterologous
expression, I have determined that the KCNA & KCNB DRK families are fa‐s channels,
while the KCNC family is fa‐i. To verify that the ratio of fa‐s:fa‐i DRK channels is
correlated with fatty acid responsiveness, I have attempted to overexpress a fa‐i
channel (KCNC1) or a fa‐s channel (KCNA5) in an enteroendocrine cell line (STC‐1). STC‐1
cells respond to polyunsaturated fatty acids (PUFAs) in a similar fashion to taste
receptor cells (TRCs). However, unlike TRCs, PUFAs (10 µM) inhibit only ~40‐50% of the
total DRK current in STC cells (Figure 5.3A) (19). Using patch clamp recording, I have
examined the effect of linoleic acid (10 µM) on DRK currents in STC cells cotransfected
with GFP and either KCNA5 or KCNC1. Overexpression of the fa‐i KCNC1 channel leads to
a marked reduction in fatty acid responsiveness (Figure 5.3B, 5.3D). Conversely, over
expressing KCNA5 channels enhanced the fatty acid responsiveness (Figure 5.3B, 5.3D),
consistent with my model. DRK channel block by fatty acid causes depolarization of
STC‐1 cells and depolarization causes hormone release (Fig. 5.4), therefore I hypothesize
that these channels are playing a major role in fatty acid transduction in STC‐1 cells and
by consequence in fatty acid induced satiety hormone release. Having elucidated much
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of the upstream pathway for linoleic acid transduction, questions regarding the role of
fatty acid‐sensitive DRK channels may now be tackled.

How is Dietary Fat Recognized by the Gustatory System?
Inferences from STC‐1 Cells.
While involvement of the peripheral gustatory system in detection of dietary fat
intake is unequivocal, there have been very few studies aimed at identifying gustatory
mechanisms by which dietary fat is recognized. Recent findings from our laboratory and
others have identified various fatty acid activated receptors (CD36, DRKs, GPR40,
GPR41, GPR43, GPR120, and GPR84) in taste receptor cells from the tongue (4, 5, 10,
13). Matsumura and colleagues have shown that GPR120 is expressed in Type II taste
receptor cells (those cells containing alpha gustducin, PLCβ2 and TRPM5) on the tongue
(12), a profile similar to that found in STC‐1 cells. Throughout this dissertation, the case
has been made of the utility of the STC‐1 cells as a model for chemosensory cells, like
taste cells. Based on my work in STC‐1 cells, I believe there are important parallels to
our findings and how the gustatory system recognizes and responds to fatty acids. Thus,
because of its critical importance in fatty acid signaling in STC‐1 cells, it will be very
interesting to examine the involvement of TRPM5 in detection of cis‐polyunsaturated
fatty acids, such as linoleic acid, in the taste bud. TRPM5 null mice would provide an
exceptional model to determine the role of TRPM5 in gustatory chemoreception of
dietary fat.
The fatty acid binding protein, CD36, has been implicated in transduction and
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recognition of fatty acids in the gustatory system. Results from CD36 knockout mice
using a variety of approaches (1, 3, 10, 18) have demonstrated unequivocally that this
protein is important for fatty acid signaling in the gustatory system. How CD36 directly
contributes to the signal transduction pathway, however, remains an open question.
While it may act to transport fatty acids across the taste cell membrane where they
could directly affect intracellular signaling, an equally likely scenario implies that it may
act as a binding or chaperone protein to facilitate fatty acid interactions with receptors
or channels. Specific experiments designed to distinguish among these possibilities are
critical to determine the role of this important protein. Here, too, the utility of STC‐1
cells may help answer questions regarding the role of CD36. In the course of my
research, I have found that STC‐1 cells express CD36. Thus, using strategies similar to
those employed in the current research (RNA interference, over expression of CD36,
pharmacological block of CD36), it should be possible to determine whether CD36 is
playing any role in PUFA initiated signaling that leads to CCK or GLP‐1 secretion. As the
case for TRPM5, the extension of these data from STC‐1 cells will contribute to our
understanding of taste signaling for dietary fat.

Implications for Other Areas: Fatty Acid Signaling in the Brain?
Specific brain regions, including hypothalamus, are capable of gathering body’s
nutritional information in order to implement certain behavioral and metabolic
responses to changes in fuel availability. In specific, circulating long chain fatty acids can
convey body’s nutritional status to various hypothalamic centers (9). The

137
intracerebroventricular administration of physiological concentration of oleic acid (long
chain fatty acids) has been shown to induce reduction in food intake and liver glucose
production (8, 14). So far, circulating long chain fatty acid‐induced regulation of feeding
behavior and glucose production is largely attributed to increased cellular long chain
fatty acyl‐CoA pools in the hypothalamus (8). These increased levels of long chain fatty
acyl‐CoAs in the hypothalamus signal an energy ‘surplus’ in hypothalamus and activate
neural pathways involved in regulations of food intake and glucose production (9).
However, there are not very many studies that examine electrophysiological responses
(measurement of membrane potential and intracellular calcium concentration) to long
chain fatty acids in hypothalamic neurons involved in energy balance. Based on recent
discoveries of various fatty acid activated receptors and my current finding that long
chain fatty acids are capable of altering the electrophysiological properties of the cells
by activating GPR120, I hypothesize that fatty acid activated receptors may also mediate
fatty acid sensing in hypothalamus.

The Validation of TRPM5: Exploration of Another Pathway.
My research on fatty acid signaling (Chapter 2) led to a specific conclusion
regarding the importance of TRPM5 in this transduction pathway. Indeed, inhibiting or
knocking down expression of TRPM5 abrogated the response to linoleic acid. I was very
skeptical about involvement of TRPM5 in linoleic acid transduction pathway based on
the fact that so far nobody was able to record the activity of TRPM5 channels (in native
cells) in response to extracellular ligands (linoleic acid, bitter compounds) of upstream
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GPCRs. Because of this initially unexpected outcome, I felt it was critical to validate the
TRPM5‐mediated responses in a pathway where the role of this channel was more well
established. My work in Chapter 3 mainly focused on recording and characterization of
TRPM5 activity in response to structurally diverse bitter compounds denatonium
benzoate (DB) and phenylthiocarbamide (PTC). Previous research has shown that
TRPM5 channels are involved in bitter taste transduction (20) in taste receptor cells.
But, activity of TRPM5 channels has never been recorded in response to bitter
compounds in native chemosensory cells. Moreover, at the cellular level, TRPM5 ion
channels have never been shown to be involved directly in bitter transduction pathway
in native cells. In particular, my research reported in Chapter3 provides the first direct
empirical support for the role of TRPM5 in bitter signaling pathways in a chemosensory
cell line. Thus, our data and that of others supports a pathway whereby bitter stimuli,
like PTC and DB, activate specific T2Rs (GPCRs) leading to the activation of PLC and the
generation of IP3 and DAG. IP3‐mediated calcium release (or other pathways) activates
TRPM5. Monovalent cation influx through TRPM5 depolarizes the STC‐1 cell, opening
voltage‐gated calcium channels and allowing the calcium influx required for release on
hormones like CCK and GLP‐1, from these enteroendocrine cells. In view of the results
presented in this study, it is plausible that luminal bitter tastants (potentially toxic
compounds) trigger intracellular rise in calcium levels (by activating TRPM5‐mediated
bitter transduction pathway) in enteroendocrine cells leading to release of GI peptides
(such as CCK, GLP‐1), that activate neural pathway involved in aversive behavior.
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Interestingly, CCK, GLP‐1, and PYY, like bitter stimuli, mediate an aversive food response
in rodents (2, 6, 17) and the results from previous findings show that bitter stimuli
trigger the release of CCK. Collectively, these findings bring up an attractive possibility
that the release of GI peptides such as CCK, GLP‐1 in response to bitter stimuli could
play a role in protecting the organism against potentially toxic (bitter) substances.
In spite of the data supporting the involvement of TRPM5 channels in bitter taste
transduction, there have been mixed views regarding the mechanism for activation of
TRPM5. Some studies show that TRPM5 channels can be directly activated by
intracellular calcium ions (7, 11, 16), or the depletion of calcium ions from intracellular
stores (15). However, other studies showed that TRPM5 is not activated by calcium, IP3,
or depletion of intracellular calcium stores (20). Despite these controversies, the most
popular view is that TRPM5 is activated directly by intracellular calcium ions. In the
course of this work, however, I have come to question this prevailing theory that TRPM5
is activated directly by intracellular calcium ions. I draw this conclusion based on the
following arguments: 1) In all those studies TRPM5 has micromolar sensitivity to calcium
ions; however calcium levels in chemosensory cells in response to bitter stimuli reach
only higher nanomolar levels; 2) most of the studies were done in cell lines, it remains
possible that the heterologously expressed channels do not fully recapitulate the
properties of native channels; 3) recording activity of TRPM5 channels in response to
calcium does not necessarily mean that TRPM5 is activated by a similar molecular
mechanism in the intact (i.e. native) bitter transduction pathway. The use of a fast, high
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affinity calcium chelator, such as BAPTA, in intracellular solution and recording the
activity of TRPM5 channels in response to bitter compounds would give us a concrete
idea whether TRPM5 is activated by calcium ions or any other alternative molecular
mechanism. Again, the use of STC‐1 cells, which recapitulate all the properties of the
bitter taste transduction pathway, would be an ideal model to test how TRPM5 channels
are activated in native cells. As an initial approach to investigate molecular mechanism
for activation of TRPM5 channels in STC‐1 cells, I would try to examine roles of DAG and
IP3 (products of PIP2) in the activation of TRPM5 channels in bitter transduction
pathway.

The Utility of a Nanoparticle‐Mediated Approach
for Drug Delivery to EECs
The final goal of my dissertation work was to develop and characterize
nanoparticles

mediated

drug

delivery

system

for

delivering

pharmaceutical

agents/genes specifically to the cells (Type‐I enteroendocrine cells/STC‐1 cells) involved
in control of food intake. In Chapter 4, as an initial approach to meet this objective, I
fabricated nanoparticles from the biodegradable polymer PLGA (poly (D,L‐lactide‐co‐
glycolide)). Next, I characterized various physio‐chemical properties of PLGA
nanoparticles. In order to optimally deliver payloads inside cells, I performed time,
concentration and size dependent intracellular uptake studies in STC‐1 cells. Results of
my intracellular uptake studies clearly demonstrate that 100 nm PLGA nanoparticles are
efficiently taken up by STC‐1 cells and thus can be used as drug delivery vehicles in
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enteroendocrine cells. Further, I examined effects of internalized PLGA nanoparticles on
elelctrophysiological properties of STC‐1 cells. The results demonstrated that
internalized PLGA nanoparticles neither cause measurable cytotoxicity in STC‐1 cells nor
interfere with both voltage gated ion channel function and signaling pathways that lead
to secretion of satiety peptides like CCK and GLP‐1. In spite of the above mentioned
preliminary data, further validation of PLGA nanoparticles with respect to drug
encapsulation efficiency and drug release profiles is essential.
Because of the potential of nanoparticles to be taken up into a variety of cell
types, the future experiments will attempt to specifically target nanoparticles to the
EECs. To do so, PLGA nanoparticles will be tagged with fluorescent antibodies against
the T2R receptor family, bitter taste receptors that are highly expressed in EECs.
Immunolabeling of nanoparticles permits more specific targeting; however, many
antibodies are poorly internalized. If this turns out to be the case, in order to ensure
efficient internalization of nanoparticles into EECs, incorporation of internalizable
determinants such as cationic lipids, cell penetrating peptides like HIV protein derived
transactivating regulatory protein (HIV‐TAT) and penetratin on the surface of antibody
conjugated nanoparticles will be performed.
The ultimate goal, then, will be to incorporate and deliver pharmacological agents
(intracellular ligands for GPR120, activators of TRPM5, ligand for KCNA5) or genes of
interest (gene encoding GPR120, TRPM5, KCNA5 DRKs, or CCK in an appropriate vector)
to enhance CCK release from EECs.

Though done in vitro in cultured EECs, the
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development of this technology will enable us to gather additional data, establish proof
of concept, and extend this approach to in vivo animal models where effects on food
intake can be directly assessed.
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Figure 5.1: Relative expression of fatty acid activated receptors in STC‐1 cells.

Figure 5.2: Nicardipine (blocker of L‐type voltage gated calcium channels) treatment
significantly reduced linoleic acid (30 µM) induced rise in intracellular calcium
concentration in STC‐1 cells. Data are shown mean + SEM.
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Figure 5.3 Inhibition of DRK currents in response to linoleic acid (10 µM) in
control, KCNA5 overexpressed and KCNC1 overexpressed STC‐1 cells. A: Outward K+
currents in native STC‐1 cells are inhibited ~50% by 10 μM linoleic acid. B: STC‐1 cells
transfected with KCNC1 show significantly less inhibition of K+ currents in response to 10
μM linoleic acid. C: STC‐1 cells transfected with KCNA5 DRK channels show significantly
more inhibition of outward K+ currents in response to 10 μM linoleic acid.D: Mean
residual outward K+ current in the presence of linoleic acid (10 µM) in native STC‐1 cells,
STC‐1 transfected with KCNC1 and STC‐1 transfected with KCNA5. Overexpression of
the fatty acid‐insensitive KCNC1 reduced fatty acid responsiveness while overexpression
of the fatty acid‐sensitive KCNA5 significantly increased fatty acid responsiveness in STC‐
1 cells.
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Figure 5.4: A revised working model (including CD36 and DRKs) for fatty acid
transduction in STC‐1 cells.
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